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Abstract
Large population health insurance claims databases together with operations research
and data mining methods have the potential of significantly impacting health care
management. In this thesis we research how claims data can be utilized in three
important areas of health care and medicine and apply our methods to a real claims
database containing information of over twi million health plan members. First, we
develop forecasting models for health care costs that outperform previous results.
Secondly, through examples we demonstrate how large-scale databases and advanced
clustering algorithms can lead to discovery of medical knowledge. Lastly, we build a
mathematical framework for a real-time drug surveillance system, and demonstrate
with real data that side effects can be discovered faster than with the current post-
marketing surveillance system.
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Chapter 1
Introduction
This thesis explores applications of operations research methods and data mining to
health care insurance claims data. This research was possible through collaboration
with D2Hawkeye, a medical data mining company in Waltham, Massachusetts. A
collection of members' claims has the benefit of giving a "bird's eye view" of a pa-
tient's health care, providing the opportunity to recognize patterns in a member's
records that is not visible from a single specialist's view. Large population claims
databases therefore provide a wealth of research opportunities, and together with ad-
vanced data mining models, have the potential of significantly impacting health care
management in the US. In this thesis, we research how claims data can be utilized
for cost prediction, medical knowledge discovery and drug surveilance.
Below, we give an introduction to claims data and the contents of the subsequent
chapters.
1.1 Health Insurance Claims Data
Health insurance claims data, or simply "claims data", includes two types of claims,
medical and pharmaceuitical, as well as information about the members, such as age,
gender and his/her geographical location. Medical claims data get generated when
hospitals and other health care providers send claims to third-party payers to receive
reimbursement for their services. Each time a member visits a doctor or a hospital, a
claim line gets generated with the reason for the visit, the diagnois and the procedure
performed. If multiple services are performed, a single visit might result in multiple
claim lines. The data does not include results of tests or procedures, although some-
times the results can be ineffered from the subsequent treatment. Pharmaceutical
claims data get generated when a member fills a prescription and includes, for exam-
ple, information about the drug, the prescribing doctor, and the number of days of
supply.
The value of claims data in medical research has often been questioned [36, 23] be-
cause these databases are designed for financial reasons and not for clinical purposes.
Nevertheless, claims data has been shown to be useful in many settings and is increas-
ingly being used for medical research. Examples include researching differences in the
outcomes of adherence to medication [53], in length of episodes [50], and of medical
outcomes [61] as well as identification of in-hospital complications [44]. Statistical
methods generally used when working with medical data are nicely summarized in
[37], and other work addressing issues working with health care cost data include
[65, 47].
Claims data relies on health care professionals to encode their diagnoses and proce-
dures in terms of the ICD-9-CM codes. There are numerous studies that investigate
the reliability of claims data, which compare the information in the claims data to
actual medical records; we refer the reader to [22] for a nice summary of those studies.
In short, the sensitivity1 of a diagnosis varies from 50% to over 90%, depending on
the diagnosis. Procedures in the claims data have a high correlation with the medical
record, and prescription claims have been found to be a more reliable record for drugs
actually dispensed than the medical record. In summary, claims data has limitations
to its accuracy, but the availability and the size of the data make it an attractive
1The Sensitivity of a diagnosis in a claims data is the probability of the diagnosis appearing in
the claims data among all patients with disease. A sensitivity of 100% for a diagnosis means that
for all members with the disease, the appropriate diagnosis appears in the claims data.
option when conducting research in medicine and health care.
1.2 Cost Prediction and Discovery of Medical Knowl-
edge
The rising cost of health care is one of the world's most important problems. Ac-
cordingly, predicting such costs accurately is a significant first step in addressing this
problem. In Chapter 2, we focuse on health care cost prediction. Earlier researchers
concentrated on using classical regression models or logistic regression models often
combined with heuristic classification rules [21], and traditionally, researchers have
reported the accuracy of their models using in-sample R2 . In our view, the best way
to express the predictability of a method is to perform out-of-sample experiments us-
ing different performance measures. We therefore introduce new error measures and
report our results out-of-sample, that is, on data that was not used in developing the
models. We introduce the concept of a "cost bucket" - a predefined range of cost.
We first forecast the cost bucket and then translate the prediction into dollar terms.
The "bucketing" helps reduce the noise in the data and the effects of outliers. We also
introduce a baseline method of "repeating costs," that we use to compare our results
with. We apply data-mining algorithms, in particular clustering and classification
trees, to cost prediction and outperform previously published results.
Through our work on cost prediction, we identify opportunities for medical discovery,
using an modified version of the clustering algorithm Eigencluster [3]. The algorithm
can take a global view of the data and identify new patterns and may therefore re-
veal unexpected associations among diagnoses, procedures and drugs. We identify a
recently suspected link between osteoporosis and depression. In addijton, we identify
nonsteroidal anti-inflammatory agents as a risk factor for cardiac patients. Further
analysis of the data and the existing medical literature confirmed our discoveries.
1.3 Drug Surveillance
After the withdrawal of rofecoxib (commonly known as Vioxx) from the pharmaceu-
tical market in 2004, post-FDA-approval drug safety and surveillance has come under
serious scrutiny. In a 2006 study by the Institute of Medicine, it was pointed out that
efforts to monitor the risk-benefit tradeoff of medications decreases after FDA ap-
proval, and that this issue needs to be addressed [55]. Currently the Center for Drug
Evaluation and Research, a part of the Food and Drug Administration (FDA), han-
dles the post-FDA-approval drug surveillance, which is conducted using the Adverse
Event Reporting System (AERS). The AERS is a voluntary system where patients
and health care professionals can submit reports of adverse events. Although the
system has often proved useful in identifying serious side effects of drugs, it has been
insufficient in identifying potential safety signals, as not all events (some even suggest
very few) get reported and events that can be indicators of increased risk might not
be considered important by individual patients or health care professionals.
Claims data holds great potential for real-time drug surveillance, due to its fast avail-
ability and size, which is crucial when trying to detect rare events. In Chapter 3, we
develop a framework for drug surveillance and address two of its fundament issues:
a) how do we choose comparison groups? and b) how do we compare the two groups?
We test serveral methods on real data from D2Hawkeye and report on the results.
1.4 Contributions
There are several contributions of this thesis. In our work on cost prediction we
indentify the past cost trajectory to be a powerful predictor of future cost. This
observation could refocus the research effort in the area away from detailed disease
based modeling. We also raise questions about the limitations and validity of current
measures of predictive accuracy and propose alternatives, guided by the use of the
cost predictions. Finally, we introduced new methods that have not been applied
in this context before, and showed that they outperform previous published results.
We discuss how medical knowledge is often obtained from small studies. As a result,
large-scale claim databases has the potential to add to that knowledge, and we provide
two examples to support that argument. Lastly, in Chapter 3 we perform, to our
knowledge, the first full drug-surveillance experiment, that tests across the whole
spectrum of possible side effects. Our findings discourage the use of a comparison
population as a direct comparison, the current method of choice. Our work shows
that a successful drug-surveillance system can be built, based on claims data analysis
and could become one of FDA's standard tools for post-marketing surveillance.

Chapter 2
Prediction of Health Care Costs
and Algorithmic Discovery of
Medical Knowledge
2.1 Introduction
The predictive power of claims data became a topic of research in the 1980s [63]
and numerous studies since have established the predictive power of administrative
data on health care costs, [10, 64, 27, 63]. Van de Ven et al. [59] provides an in-
sightful overview of the developments in risk based predictive modeling prior to 2000.
Cumming et al. [21] presents a comparison analysis of different predictive models de-
veloped in the insurance industry for both risk assessment and population health care
cost prediction. The models compared used both diagnosis and prescription data and
the study further validated the predictive power of claims data. Earlier researchers
have concentrated on using classical regression models [63, 10, 64, 54] when predict-
ing total health care costs or logistic regression models, [43, 57] to identify high risk
members. Often these regression models are combined with heuristic classification
rules. There has also been significant work in creating comorbidity' scores from ad-
'Comorbidity is defined as coexisting medical conditions.
ministrative data, as a method to account for comorbidity differences of comparative
populations in medical research [41], to design fair reimbursement plans [59, 25] and
as a basis for predictive modeling of health care costs [10, 27, 18]. Numerous studies
that predict health care cost, based on data other than claims data are available,
examples include [29, 52].
In our view, the best way to express the predictability of a method is to perform
out-of-sample experiments (that is, use data that the method has not seen) using
different performance measures. To the best of our knowledge, the majority of earlier
regression studies do not report on the predictability of the method in an out of sam-
ple experiment, with a few exceptions [54, 24]. Traditionally [21] R 2 (or adjusted R 2)
have been the measures used to evaluate predictive models but there are some serious
drawbacks to its use, which in our opinion makes it unsuitable for a study like the
one presented in this chapter. The R 2 measure is a relative, not an absolute measure
of fit. It measures the ratio of the improvement of predictability (as measured with
the sum of squares of the residuals) of a regression line compared with a constant
prediction (see for example, [12]). In particular, comparisons based on R 2 can be
made when different regression models on the same data set are being compared,
but it is not very meaningful to base comparisons with other methods such as the
methods we utilize in this chapter. Depending on the purpose of the cost prediction
(medical intervention, contract pricing, etc.) different error measures may be more
appropriate and better suited than R2 . We therefore define new error measures that
better describe the prediction accuracy in a variety of ways.
Our objectives in this chapter are to utilize modern data mining methods, specif-
ically classification trees and clustering algorithms, and claims data from more than
800,000 members over three years to provide predictions of health care costs in the
third year, by applying data mining methods to medical and cost data from the first
two years. We quantify the accuracy of our predictions by applying the models to a
test sample of more than 200,000 members. The key insights obtained are: a) our
data mining methods provide accurate predictions of health care costs and represent
a powerful tool for prediction, b) the patterns of past cost data are strong predictors
of future costs, c) medical information adds to prediction accuracy when used in the
clustering algorithm, while with classification trees, cost information alone results in
similar error measures.
The rest of the chapter is structured as follows: In Section 2.2, we describe the
data and define the performance measures we consider and in Section 2.3, we present
the two principal methods we use: classification trees and clustering algorithms. In
Section 2.4, we report on the performance of classification trees and clustering re-
spectively in forecasting health care costs, and in Section 2.6, we briefly discuss our
conclusions and future research directions.
2.2 The Data and Error Measures
This study uses health care data generated when hospitals and other health care
providers send claims to third party payers to receive reimbursement for their ser-
vices. The study period is from 8/1/2004-7/31/2007, split up into a 24 month long
observation period from 8/1/2004 - 7/31/2006 and a 12 month result period from
8/1/2006 - 7/31/2007. We build our models using information from the observation
period to predict outcomes in the result period.
Our data set includes the medical claims data for 838,242 individuals from a com-
mercially insured population, from 2866 employers and employer groups across the
country. The data set includes both medical and pharmaceutical claims, as well as
information on the period an individual (and his/her family) was covered by the in-
surance policy. The data also contains basic geographic information such as age and
gender. All members have eligibility starting no later then 8/1/2005 and ending no
sooner than 8/1/2006, and all employers had continuous coverage starting no later
than 8/1/2005 and ending no sooner than 8/1/2007. This ensures that every employee
has at least 12 months of data in the observation period and that big populations do
not drop out during the result period, as a result of change in an employers insurance
carrier. Out of the 838,242 members, 730,918 have eligibility stretching beyond the
result period. The difference, just over 108,000 members or 13.8% of the population,
drop out during the result period. This is most often due to employee turnover which
is expected to be around 15% per year. A smaller portion, expected around 3,000
members (based on gender and age distribution of the population) do not have full
coverage due to death. Our analysis has shown that including the population with
partial coverage in the result period improves the error measures, and therefore in
the interest of simplicity we build our models using the population with full coverage
in the result period and report these results.
We split the data set, by random assignment, into equally sized parts: a learning
sample, a validation sample, and a testing sample. The learning sample is used to
build our prediction models, while the validation sample is used to evaluate the per-
formance of the various models. The test sample was set aside while building and
calibrating the models, and only used at the very end of the experiment, to report
results of the finalized models. We believe that this methodology appropriately vali-
dates our conclusions.
2.2.1 Aggregation of the Claims Data
The claims include diagnosis, procedure and drug information. The diagnosis data
is coded using the ICD-9-CM [1] (International Classification of Diseases, Ninth Re-
vision, Clinical Modification) codes, the universal codes for medical diagnoses and
procedures. The procedures are coded under various coding schemes: ICD9, DRG,
Rev Coding, CPT4 and HCPCS; over 22,000 codes altogether. Furthermore, the data
includes pharmacy claims, that is, it contains information about which, if any, pre-
scription (and some limited over the counter) drugs a health plan member is taking,
coded in terms of 45,972 drug codes [5].
Claims data relies on health care professionals to encode their diagnoses and pro-
cedures in terms of the ICD-9-CM codes. Although coding for medical claims starts
with a clinician, it is most often completed and submitted by a separate dedicated
billing operator. Because of the inevitable variations in interpretations introduced by
these practices, and to reduce the data to a more manageable size, we chose to use
coding groups rather than individual codes. We reduced over 13,000 individual diag-
noses to 218 diagnosis groups. Medical procedures and drug categories were likewise
grouped. Over 22,000 individual procedures are classified into 180 procedure groups,
and over 45,000 individual prescription drugs were classified into 336 therapeutic
groups. Also included in the analysis are over 700 medically developed quality and
risk measures which designate hazardous clinical situations (for example patients with
a pattern of ER care without office visits, diabetics with foot ulcers, etc.) We also
count the number of diagnosis, procedures, drugs and risk factors that each member
has and include it as additional variables. In summary, the predictive medical vari-
ables include: the diagnosis groups, the procedure groups, the drug groups, the risk
factors that we have developed, and their count, for a total of close to 1500 possible
medical variables. We refer the reader to Appendix 2.A for more details.
2.2.2 Cost and Demographic Data
In addition to the medical variables, we utilize 22 cost variables, since we believe
that cost information gives a global picture of the health of a member and include
age and gender as well. In order to capture the trajectory of the medical costs (as a
proxy of the overall medical condition) we use the monthly costs for the last twelve
months in the observation period, the total drug cost and the total medical cost over
the entire observation period, as well as the overall cost in the last 6 months and
the last 3 months of the observation period. Furthermore, in order to capture the
pattern of costs, we developed a new indicator variable that captures whether or not
the member's cost pattern exhibits a "spike" pattern, i.e., a sudden increase followed
by a sudden decrease in cost. To demonstrate this idea let us consider Figure 2-1
that depicts the monthly cost of two members in the last twelve months of the ob-
servation period. While both members have around $98,000 of paid claims, Member
A has constant relatively high medical costs (a typical pattern for a member with a
chronic condition), while Member B has a spike in the cost profile (a typical pattern
for a member with an "acute" condition). The key idea here is that while constant
high medical costs have a strong tendency to repeat in the future, a cost pattern that
exhibits a spike might have a low risk of high future health care costs, for example
in the case of pregnancy complications, accidents, or acute medical conditions like
pneumonia or appendicitis.
x 104
0
0
Monthly Costs for Two Members
2 4 6 8 10
month
Figure 2-1: 12 months health care costs of two members, with overall cost of $97,500
and $98,100 respectively. A cubic spline curve is fit to the data for easier viewing.
The cost profile for Member A has the characteristics of a chronic illness while, the
characteristics of member B's profile is "acute". The diagnoses behind the most
expensive claims of member A are lymphema and respiratory failure. The reasons
behind the highest claims of member B reflect complications of labor.
Moreover, we used the following additional four variables: the maximum monthly
0
cost, the number of months with above average cost, positive and negative trend in
the last months of the observation period.
Finally, we used gender and age as additional variables. Table 2.1 summarizes all
the variables used in the study and more details are provided in Appendix2.A.
Variable
Number Description
1 - 218
219- 398
399- 734
735- 1485
1486- 1489
1490- 1780
1522-1523
Diagnosis Groups, count of claims with diagnosis codes from each
group
Procedure Groups
Drug Groups
Medically defined risk factors
Count of members diagnosis, procedures, drugs and risk factors
Cost variables, including overall medical and pharmacy costs, acute
indicator and monthly costs
Gender and age
Table 2.1: Summary of the Data Elements Used.
2.2.3 Cost Bucketing
The range of paid amounts for members in the learning sample during the result pe-
riod is from no cost up to $ 710,000. The population's cumulative cost exhibits known
characteristics; 80% of the overall cost of the population originates from only 20% of
the most expensive members. In Figure 2-2, that shows the cost characteristics of
our population, we note that for our sample around 8% of the population contributes
70% of the total health care costs.
In order to reduce noise in the data and at the same time reduce the effects of
extremely expensive members (who can be considered outliers) we partitioned the
members' costs into five different bands or cost buckets. We partition in such a way
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Figure 2-2: Cumulative health care costs of the result period for members in the
learning sample. On the x-axis is the cumulative percentage of the population and on
the y-axis is the cumulative percentage of the overall health care costs. For example
we note that 8% of the population (the most expensive members ) account for 70%
of the overall health care costs.
that the sum of all members' costs is approximately the same in each bucket, i.e.,
the total dollar amount in each bucket is the same (approximately $117 million per
cost bucket). We chose five buckets because it ensures a large enough number of
members in the top bucket (we have 1175 members in the learning sample in bucket
five). Table 2.2 shows the range of each bucket, the percentage and the number of
members of the learning sample that are in each bucket.
The knowledge of the predicted bucket of a member is valuable to health care man-
agement professionals. The buckets from one through five can be interpreted as rep-
resenting low, emerging, moderate, high and very high risk of medical complications.
Percentage of Number of
Bucket Range the Learning Sample Members
1 <$3,200 83.9 % 204,420
2 $3,200-$8,000 9.7 % 23,606
3 $8,000-$18,000 4.2% 10,261
4 $18,000-$50,000 1.7% 4,179
5 > $50,000 0.5% 1,175
Table 2.2: Cost Bucket Information. Cost bucket ranges and fraction of the learning
sample in each bucket (last 12 months of the observation period costs). The sum of
members' costs that fall in any one of the buckets is between $116 and $119 million.
Members predicted to be in buckets 2 and 3 are candidates for wellness programs,
members predicted to be in bucket 4 are candidates for disease management pro-
grams, while those members forecasted to be in the top bucket are candidates for
case management programs, the most intense patient care program.
2.2.4 Performance Measures
We will measure the performance of our models with three main error measures: the
hit ratio, a penalty error and the absolute prediction error (APE). To be able to
compare our results to published studies we also include R2 and truncated R 2, and
introduce a new similar measure IRI. We provide some additional insights into R 2 in
Section 2.2.4 and define the new error measures in Section 2.2.4.
Definition of Error Measures
The Hit Ratio
We define the hit ratio to be the percentage of the members for whom we forecast
the correct cost bucket.
The Penalty Error
The penalty error is motivated by opportunities for medical intervention and is there-
fore asymmetric. There is greater penalty for underestimating higher costs, consistent
with the greater medical and financial risk in missing these individuals. The penalty
of misidentifying an individual as high risk, whose actual costs are low, is smaller
than the opposite case, as little harm or cost ensues in this instance. Therefore, the
penalties for underestimating a cost bucket are set as twice those for overestimating
it, the estimated opportunity loss by doctors. Table 2.3 shows the penalty table for
the five cost bucket scheme. We define the penalty error measure to be the average
forecast penalty per member of a given sample.
Outcome
12345
102468
210246
Forecast 3 2 1 0 2 4
432102
543210
Table 2.3: The Penalty Table defines the penalty error measure for the five cost
buckets. A perfect forecast results in an error of zero.
The Absolute Prediction Error
The absolute prediction error is derived from actual health care costs. We define the
absolute prediction error to be the average absolute difference between the forecasted
(yearly) dollar and the realized (yearly) dollar amount. As an example, if we forecast
a member's health care cost to be $500 in the result period, but in reality the mem-
ber has overall health care cost of $2,000, then the absolute predicted error for the
member is 1$500 - $2, 0001 = $1, 500. We define the absolute prediction error (APE)
to be the average error over a given sample. APE has been used in recent studies
[21, 54, 25] together with the traditional R2 . An advantage of APE is that it does not
square the prediction errors, which makes it less sensitive to outliers (members with
extreme health care cost). This is of special concern due to the nature of health care
cost data, as there are a few individual members with very unpredictable high costs.
The R2 Measure
R2 is defined as
R2= 1- i(ti- fi )
2
i(ti - a)2
where fi is the forecasted cost of member i, ti is the true cost of member i and a
is the average health care cost in the result period. If we look at the contribution
of members in the observation period's cost buckets to the sum in the denominator,
it varies greatly as shown in Table 2.4. The second column has the fraction of the
learning sample in each bucket, and in the third column the contribution to the sum
in the denominator. We note that 27.9% of the sum is contributed by the 0.5% of
members in the top bucket in the observation period. R 2 is therefore disproportion-
ably influenced by the members in the top bucket.
R2 squares each prediction error, which makes it very sensitive to prediction error
for members with high health care costs. A model that does very well for the major-
ity of the population might therefore have low R 2 due to few extreme unpredictable
outliers (for example, members with a sudden onset of a serious condition). In the
literature, researchers have dealt with this fact by truncating the health care cost.
We denote the resulting R 2 when claims are truncated to $100,000 by R2oo, and the
fourth column of Table 2.4 shows the contribution to the denominator sum in that
case. By truncating the these members the contribution in the denominator sum of
the top bucket reduces to 16%, close to that of bucket 2 through 4.
A natural measure of health care cost prediction is the absolute value of the prediction
error. We therefore define a new R-like measure, that has some of the same properties
as R 2,
R = 1
- 
Eti - filSIti - m i'
where m is the sample median. We note that IRI = 0 if we predict the median of the
sample for all members, and |R| = 1 if ti = fi for all members i. In the same way
as R 2 measures the reduction in the residuals squared, |Rl measures the reduction
01
% of the % of Overall % of Overall
Learning % of Overall E((ti - a) 2) % of Overall E(lti - m)
Bucket Sample E((ti - a) 2) Truncated E(lti - ml) Truncated
1 83.9% 30.8% 36.1% 47.0% 48.3%
2 9.7% 12.4% 15.9% 20.0% 20.7%
3 4.2% 14.0% 14.3% 14.0% 14.2%
4 1.7% 14.9% 16.9% 10.9% 10.6%
5 0.5% 27.9% 16.8% 8.2% 6.2%
Table 2.4: Analysis of Denominator Sums of R 2 and JRI. Contribution to denominator
sums of R 2 and the |RI error measures as a function of the bucketed cost in the last
12 months of the observation period (numbers are based on the testing sample).
in the sum of absolute values of the residuals. In the last two columns of Table 2.4,
we summarize the contributions to the RI| denominator sum for the populations. We
note that the contribution is strictly decreasing in the observation period bucket,
and is less affected by truncation (noted by IRiooI). We conclude that JRI is less
sensitive to outliers than R 2 and therefore possibly better suited for health care cost
predictions.
2.3 Methods
2.3.1 The Baseline Method
In order to make meaningful comparisons, we define a baseline method against which
we compare the results of the prediction models. As our baseline method, we use the
health care cost of the last twelve months of the observation period as the forecast of
the overall health care cost in the result period. Since current health care cost is a
strong indicator of a person's health, this baseline is much stronger than, for exam-
ple, random assignment. Table 2.5 shows how the population falls into the defined
cost buckets in the last 12 months of the observation period and the results period.
As an example, close to seventy percent of the population are in bucket one in both
periods. We further note that for members that fall into cost buckets 1 through 4
in the observation period, the most common bucket in the result period is bucket
one. On the other hand, for members who fall into cost bucket 5 in the observation
period the most common result period bucket is bucket 5. This can be interpreted
as most members who are experiencing moderate cost are, most commonly, getting
better, while those in the most expensive bucket have a greater tendency to incur
high medical costs.
Last 12 Month Observation Result Period Cost Bucket
Period Cost Bucket 1 2 3 4 5
1 75.63% 5.54% 1.88% 0.66% 0.20%
2 5.03% 2.98% 1.19% 0.39% 0.11%
3 1.81% 1.01% 0.91% 0.39% 0.08%
4 0.51% 0.38% 0.34% 0.38% 0.11%
5 0.10% 0.08% 0.08% 0.10% 0.13%
Table 2.5: The Cost Bucket Distribution of Members in the Testing Sample.
Table 2.6 summarizes the baseline forecast for all error measures. The baseline pre-
diction model correctly predicts 80.0% of the members, the average penalty error is
0.431 and the absolute prediction error is $2,677. In order to get a deeper under-
standing of the baseline method, we examine the effectiveness of the baseline method
with respect to the buckets in the observation period. From Table 2.6 we observe for
example, that for bucket 1 members the hit ratio is 90.1%, the penalty error is 0.287
and the absolute prediction error is $1,279. The fact that most of the members are
in bucket 1, have low health care costs and continue to have low health care costs
in the result period significantly affects the baseline error measures. Note that the
performance measures worsen with each increasing cost bucket.
2.3.2 Data Mining Methods: Classification Trees
Classification trees [15] have been applied in many fields such as finance, speech
recognition and medicine. As an example, in medicine they have been applied to
develop classification criteria for medical conditions such as osteoarthritis of the hip
Table 2.6: Performance measures of the baseline method overall and by cost bucket.
The cost buckets refer to the cost in the last 12 months of the observation period.
[9], the Churg-Strauss syndrome [48] and head and neck cancer [60]. Classification
trees recursively partition the member population into smaller groups that are more
and more uniform in terms of their known result period cost. This partition can
be represented as a tree, and this graphical representation makes classification trees
easily interpretable and therefore models that build on them can be medically verified.
As an example, consider the simplified case of a data set having information on
only three diagnoses in the observation period: coronary artery disease (CAD), di-
abetes and acute pharyngitis, as well as the cost bucket of the result period. The
classification tree built on this data might result in the classifier depicted in Table
2.7. The classifier can be used to predict the result period's health care cost for any
unseen member. Assuming we have a new member for whom we want to predict a
cost bucket, we first look at whether or not he/she has been diagnosed with CAD.
If not, we predict the member to be in cost bucket one next period. If the member
has been diagnosed with CAD we examine whether he/she has been diagnosed with
diabetes. If he/she has, we predict the member to be in cost bucket five, and in cost
bucket three otherwise. We refer the interested reader to Appendix 2.B for details.
Running the classification tree algorithm on the full data set results in more com-
plicated classifiers than the one depicted in Table 2.7. Tables 2.8 and 2.9 describe
characteristics of subgroups predicted to be in bucket 5 and 4 by these more compli-
cated trees. These scenarios demonstrate how the trees use both cost and medical
Bucket Hit Ratio Penalty Error APE ($)
all 80.0% 0.431 2,677
1 90.1% 0.287 1,279
2 52.3% 0.992 4,850
3 41.7% 1.358 9,549
4 30.5% 1.669 21,759
5 19.3% 1.825 75,808
Table 2.7: An example of a classification tree, built on data that has only information
about three diagnosis, CAD, diabetes and acute pharyngitis from the observation
period and the cost bucket of the result period. We note that acute pharyngitis
does not appear in the tree, which makes intuitive sense as we do not expect acute
pharyngitis to affect the following year's health care costs.
information along with age to identify the risky members of the population.
Examples of members predicted to be in cost bucket 5 in the result period
* Members with overall costs between $12,300 and $16,000 in the last 12 months
of the observation period and have acute cost profiles. The members take no
more than 14 different therapeutic drug classes during that period, and have
not had a heart blockage followed by dose(s) of amiodarone hcl. They have
more than 15 individual diagnosis and at least one of the following condi-
tions: a) have been in the ICU because of Congestive Heart Failure , b) have
Chronic Obstructive Pulmonary Disease with more than one prescription for
Macrolides or Floxins c) have Renal Failure with more than one hospitaliza-
tion in the observation period or d)have both Coronary Artery Disease and
Depression.
* Members with more than $24,500 in costs in the observation period, an acute
cost profile and a diagnosis of secondary malignancy (cancer).
* Members in cost bucket 2, with non-acute cost profile and between $2,700 and
$6,100 in costs in the last 6 months of the observation period, and with ei-
ther a) Coronary Artery Disease and Hypertension receiving antihypertensive
drugs or b) has Peripheral Vascular Disease and is not on medication for it.
* Members in cost bucket 2, taking between 15 and 34 different therapeutic
drug classes during the observation period, with non-acute cost profile and
between $1,200 and $4,000 paid in the last 6 months of the observation period
and finally have a Hepatitis C related hospitalization during the observation
period.
* Members in cost buckets 2 and 3 with non-acute cost profiles, less $2,400
in pharmacy costs and on fewer than 13 therapeutic drug classes, but have
received Zyban (prescription medication designed to help smokers quit) after
a seizure.
Table 2.8: Examples of members that the classification tree algorithm predicts to be
in bucket 5.
Examples of members predicted to be in cost bucket 4 in the result period
* Members in cost buckets 2 through 5, that have taken more than 34 thera-
peutic drug classes during the observation period.
* Members in cost bucket one that have inpatient days (have been in a hospital)
in the last three months with around $1,300 dollars in health care costs in the
last 3 months.
* Women in cost bucket one that have between $1,300 and $1,500 in cost in the
last 6 months of the observation period, that do not have Renal failure, but
have taken Arava (disease-modifying anti-rheumatic drug) within 180 days
prior to delivery and do not have prescribed prenatal vitamins during preg-
nancy.
* Members in cost bucket one, who have more than $1,700 in health care costs in
the last 6 months of the observation period, that have non-acute cost profiles
and have hypertension but no lab test in the observation period.
* Members with more than $24,500 in healthcare costs in the observation pe-
riod but less than $3,200 in pharmacy costs and on fewer than 14 different
therapeutic drug classes during the observation period. With non-chronic cost
profile, do not have a diagnosis of secondary malignancy, but have more than
nine office visits in the last 3 months of the observation period.
Table 2.9: Examples of members that the classification tree algorithm predicts to be
in bucket 4.
2.3.3 Data Mining Methods: Clustering
Clustering algorithms organize objects so that similar objects are together in a cluster
and dissimilar objects belong to different clusters. Our prediction clustering method
centers around the algorithm behind EigenCluster, a search-and-cluster engine devel-
oped in [38]. The clustering algorithm, when applied to data automatically detects
patterns in the data and clusters together members who are similar. We adapted
the original clustering algorithm for the purpose of health care cost prediction. We
first cluster members together using only their monthly cost data, giving the later
months of the observation period more weight than the first months (see Appendix
2.C.) The result places members within a particular cluster who all have similar
cost-characteristics. Then for each cost-similar cluster we run the algorithm on their
medical data to create clusters whose members both have similar cost characteristics
as well as medical conditions. We then assign a forecast for a particular cluster based
on the known result period's costs of the learning sample. To illustrate let us give an
example (details on the algorithm can be found in Appendix 2.C). We start with a
cluster, found by the algorithm using cost characteristics only. The cost profiles of
the members are shown in Figure 2-3. We note that all members have relatively low
cost until the last six months of the observation period, but a greater cost in the last
months of the period.
The key observation is that when using cost information only we are not able to
distinguish between the members in the cluster. The algorithm uses medical informa-
tion to identify subgroups within the cost cluster and partitions the members into two
sub clusters. Table 2.10 shows some of the medical characteristics with the greatest
difference in prevalence between the two groups.
The first cluster consists of members that have pathology, cytopathology, infusions
and other indicators of cancer indicating a potentially serious health problem that is
likely to lead to higher health care costs in the future. The second cluster on the other
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Figure 2-3: The monthly costs of the last 12 months of the observation period for all
members of a cost similar cluster.
hand consists predominantly of members who are in physical therapy and have had
orthopedic surgery and have other musculoskeletal characteristics. We can expect
that these members will be getting better, and thus have lower health care costs in
the following year.
Frequency in Frequency in
Cluster One Cluster Two Description
18% 72% Physical therapy
29% 83% Durable medical equipment
14% 66% Orthopedic surgery, exclude endoscopic
4% 48% Osteoarthritis
39% 3% Risk factor: amount paid for injectables greater
than $4,000.
71% 38% Pathology
32% 0% Hematology or oncology infusions
7% 38% Rehab
21% 52% Musculoskeletal disorders
25% 3% Emetics
25% 3% Blood products or transfusions
18% 0% Cancer therapies
Table 2.10: Some of the features that distinguish between cost similar members and
separates them into two medical sub clusters. The first two columns show the per-
centage of members of each cluster who have a certain diagnosis, have had a procedure
or are taking a drug.
2.4 Results
2.4.1 Performance of the Data Mining Methods
We ran the classification tree algorithm using the learning sample and calibrated the
algorithm using the validation sample. We built three distinct classification trees, one
for each of the three performance measures. Once we had found the right tree for each
error measure we used it to classify the testing sample and we report those results.
Similarly we ran the clustering algorithm. The resulting clusters contain groups of
members with similar cost characteristics and often similar medical characteristics.
For each cluster we assign a prediction based on the learning and validation samples
and apply it to the testing sample. We report on the performance of the algorithms
on the aggregate level first and then by bucket.
Hit Ratio (%) Penalty Error APE ($)
Bucket Trees Cluster BL Trees Cluster BL Trees Cluster BL
all 84.6 84.3 80.0 0.386 0.374 0.431 2,243 1,977 2,677
1 90.2 89.9 90.1 0.275 0.259 0.287 1,398 1,152 1,279
2 60.2 58.7 52.3 0.864 0.884 0.992 4,158 4,051 4,850
3 51.9 52.7 41.7 1.038 1.071 1.358 6,598 6,585 9,549
4 43.3 44.4 30.5 1.241 1.177 1.669 12,665 11,116 21,759
5 36.9 42.7 19.3 1.405 1.170 1.825 36,541 31,613 75,808
Table 2.11: The Resulting Performance Measures. The top line shows the measures
for the whole population, followed by the measures broken down by the observa-
tion's last twelve months cost buckets, for the classification tree algorithm, clustering
algorithm and the base line (BL) methodology.
Table 2.11 shows the performance measures. The trees predict the right bucket for
over 84% of the population, the average penalty is 0.385 and the absolute prediction
error is $2,243. There is a considerable improvement in all the performance measures
compared to the baseline methodology, particularly in the absolute prediction error
where the improvement is over 16%. The reduction in the penalty error is 10.5% and
there is close to 5% improvement in the hit ratio. For the clustering algorithm there
is again considerable improvement in all the performance measures compared to the
baseline method. In comparison with the classification tree algorithm, the results are
comparable, with the clustering algorithm having an edge in the absolute prediction
error.
We now take a more detailed view on the accuracy of the algorithms and break
down the performance by the observation period's cost bucket. For both algorithms
the improvements are most significant for the top buckets. For the classification tree
algorithm we note that the hit ratio almost doubles, the decrease in the penalty error
is 23% and the decrease in the absolute prediction error is over 50% for the top bucket.
The clustering algorithm similarly more than doubles the hit ratio by, decreases the
penalty error by more than 35% and the decrease in average absolute prediction error
is over 58% for the top bucket. We note that the classification tree algorithm does
a bit better on the lowest cost buckets for the hit ratio and penalty error, but the
clustering algorithm works better on the higher cost buckets.
2.4.2 Prediction Using Cost Information Only
We next investigate the predictability of health care costs using cost information
alone and compare the prediction to the results when the algorithms use both cost
and medical information. We note in Table 2.12 that for the lower buckets the results
are just as good, and in some cases slightly better. The classification trees have better
error measures for the low buckets, but the clustering algorithm does better for the
two most expensive buckets. In general, the classification trees do not benefit from
adding the medical variables.
Given that an important objective of cost prediction is medical intervention through
patient contact, models with interpretable medical details are preferred. In other
cases, simpler models, that achieve good results using only 22 cost variables, com-
pared to close to 1500 medical variables, may be preferred.
Hit Ratio (%) Penalty Error APE($)
Bucket Trees Cluster BL Trees Cluster BL Trees Cluster BL
all 84.6 84.2 80.0 0.389 0.399 0.431 2,214 2,116 2,677
1 90.1 90.1 90.1 0.279 0.282 0.287 1,395 1,269 1,279
2 60.3 57.5 52.3 0.873 0.920 0.992 4,033 4,146 4,850
3 52.3 49.9 41.7 1.025 1.093 1.358 6,462 6,580 9,549
4 42.7 41.7 30.5 1.256 1.272 1.669 12,310 12,412 21,759
5 35.2 40.5 19.3 1.367 1.220 1.825 35,875 33,907 75,808
Table 2.12: The Resulting performance measures using cost information only. The
top line shows the measures for the whole population, followed by the measures broken
down by the observation's last twelve months cost buckets, for the classification tree
algorithm, clustering algorithm and the base line (BL) methodology.
2.4.3 Comparison with Other Studies
We start by noting that, comparisons across studies that use different data sets, are
not fully valid as the average prediction error is highly dependent on the data set.
Therefore, as an indication only, we compare our average absolute prediction error to
the error reported by two other studies. [21] reports an average absolute prediction
error of 93% of the actual mean, and [54] reports an error of 98% of the actual mean.
The error for the clustering algorithm is 78.8% of the mean of our testing sample,
lower than in the two other studies.
Traditionally prediction software have aimed to minimize R2. Cumming et al. [21]
reports Ro00 from 0.140 to 0.198 (with claims truncated at $100,000) and R2 from
0.099 to 0.154 (without truncation). The trees have R2= 0.162 and R oo= 0.204, and
the clustering algorithm has R2= 0.180 and R oo= 0.219, as can be seen in the top
row of Table 2.13. In the top row of Table 2.14 we provide IRI and IR1oo0 for both
our measures as well as the baseline method.
Finally we note that summarizing the goodness of cost prediction to one number,
whether it is R2 or IRI can be misleading, and important information is lost. To
illustrate this point we have included in Tables 2.13 and 2.14 the relative reduction
in the error sum for each of the cost buckets. As an example, if Ei(ti - a)2 = 100
for the members in cost bucket one, and Ei(ti - fi)2 = 95 for the same members,
the relative reduction is (95 - 100)/100 = 0.05 or 5%. We note that for buckets 1-4,
the baseline improves over predicting the sample average, but for the most expensive
bucket, bucket 5 the baseline does worse. For the most expensive members, repeating
the current cost is not a strong prediction rule, and due to the weight that those
members carry in the R 2 measure, this results in negative R 2.
Our algorithms reduce the relative error for all cost buckets, and the reduction in-
creases with higher cost buckets, ranging from 5% to 49% for the R2 and Ro o00 measures
and from 10% to 32% for the IRI and IRlool measures. This shows that our prediction
models improve predictions for members in all buckets, most significantly for the most
expensive members.
Baseline Trees Clustering
Bucket R R R 00  R2  Roo R2  R2
all -0.102 -0.050 0.162 0.204 0.180 0.220
1 -3.3% -5.3% -5.3% -8.3% -5.0 % -7.9%
2 -5.6% -8.9% -6.3% -10.9% -5.7 % -8.6%
3 -8.7% -13.6% -12.8% -23.3% -12.7% -22.5%
4 -5.7% 1.3% -22.6% -34.1% -24.4% -36.5%
5 50.0% 60.1% -31.0% -39.4% -37.0% -49.8%
Table 2.13: The R2 , and R 0oo for the two algorithms and the baseline. Rows 1 through
5 show the relative reduction in the denominator sum for each cost bucket.
Baseline Trees Clustering
Bucket |RI IRlooI IRI IR0oo IRI IR1oo I
all -0.037 -0.013 0.171 0.182 0.182 0.194
1 -11.5% -11.9% -10.4% -10.8% -12.7 -13.1
2 -8.5% -8.8% -23.9% -24.9% -21.7 -22.4
3 10.1% 10.6% -25.0% -26.2% -24.1 -25.3
4 32.5% 35.4% -23.4% -25.4% -24.2 -26.3
5 71.0% 58.2% -16.6% -23.4% -23.7 -33.0
Table 2.14: The |RI, and IR1ool for the two algorithms and the baseline. Rows 1
through 5 show the relative reduction in the denominator sum for each cost bucket.
2.4.4 Summary of Results
In summary, we observe that the both algorithms improve predictions over the base-
line method for all performance measures and the improvement is more significant
for more costly members (higher buckets). In terms of overall performance measures
(overall hit ratio and absolute prediction error) the methods are comparable. The
clustering method results in better predictions for current high cost bucket members
and consistently better absolute prediction error, while the classification tree algo-
rithm has an edge on lower cost members when we look at the hit ratio and the
penalty error. We believe that the reason that the clustering algorithm is stronger in
predicting high cost members is the hierarchical way cost and medical information is
used. Recall that the clustering algorithm first uses cost information and then uses
medical information in situations where medical information can further discriminate
between members belonging in different cost buckets. Referring back to our clus-
tering sample, we note that all members of a cost-similar cluster have similar cost
trajectories of rising costs in the last months of the observation period. Using medical
information, the clustering algorithm is able to distinguish between two main groups
of patients, identifying one as higher risk cancer patients, predicting cost bucket 4
while predicting cost bucket 1 for the patients with musculoskeletal and orthopedic
characteristics. Where medical information is not dense, that is for members in the
lower buckets, using cost information only results in similar error measures. Further-
more, from our comparison with previous studies we find evidence that our algorithms
do well in comparison to current prediction methods, and analysis of the R2 measure
and IRI showed improved predictions for all cost buckets.
2.5 Algorithmic Discovery of Medical Knowledge
New medical information is often obtained through small controled studies tht focus
on few detailed factors rather than the big picture. Large-scale datasets coupled with
advanced algorithm have to potential to discover information, that is only visible
with large populations. Through our work on cost prediction, we have identified
opportunities for medical discovery, using an adopted version of Eigencluster. We
applied Eigencluster to selected subgroups of the populations and analyzed the results.
The algorithm can take a global view of the data and identify new patterns and
therefore reveal unexpected associations among diagnoses, procedures and drugs. In
this Chapter, we demonstrate through two examples how medical insights can be
extracted from the data.
2.5.1 Association of Estrogens with Antidepressants
The clustering algorithm has the ability to take a global view of the data and po-
tentially identify new patterns in the data. In this example, we ran the algorithm
on all women in our sample between 45 and 65 years of age. When interpreting the
resulting clustering a strong association between estrogens and antidepressants was
observed. Information on a cluster consisting of 26,651 members that demonstrates
this relationship is shown in Table 2.15.
Prevalence
50%
32%
28%
27%
22%
20%
20%
16%
14%
11%
Description
Estrogens & comb.
Antidepressants
Antihyperlipidemic drugs
Hypertension
Ace inhibitors & comb.
Beta blockers & comb.
Thyroid agents / hormones
Gastrointestinal drugs
Calcium channel blockers & comb.
Cardiac drugs
Table 2.15: Antidepressants and estrogen cluster, the top ten most distinguishing
features of the cluster. We note that both antidepressants and estrogens are among
the distinguishing features. This pattern of estrogen coupled with antidepressants
(and in some cases depression) was repeated throughout the clustering and led us to
our analysis of the relationship between estrogens and antidepressants.
After noting this relationship, we analyzed our dataset and found that the probability
of a member being on an antidepressant goes up by 166% 2 if we know the member is
2In our data we are unable to verify that all members have complete pharmacy claims data. For
comparison, we excluded all members whom we could not verify having complete pharmacy claims,
taking estrogens, compared to members not taking estrogens. The difference in the
number taking antidepressants was assessed by a z test and we found the difference
to be statistically significant at the p < 0.001 level. 3 Our observation is consistent
with recent reports of relationships between osteoporosis and depression [20, 56, 8].
2.5.2 Association of Nonsteroidal Anti-Inflammatory Agents
and Increasing Costs
Table 2.16 shows information on two additional clusters that both contain cardiac
patients from a general study that included numerous clusters. The members of the
first cluster have significantly higher health care costs (bucket 4) in the result period,
while members of the second cluster have significantly lower health care costs (bucket
2). Comparing the characteristics of each cluster, we observed that they are very
similar except for the fifth factor of the first cluster, the presence of nonsteroidal
anti-inflammatory agents4 .
This observation, together with recent reports of increased cardiac risk in patients
taking Cox 2 inhibitors, led us to analyze the costs and cardiac outcomes of members
taking Cox 2 drugs. We compared overall costs and the prevalence of CAD between
patients of the study sample who had taken only Cox 1 drugs and patients who had
taken only Cox 2 drugs, as presented in Table 2.17. Differences in Coronary Artery
Disease prevalence were significant at the p<0.001 level. Since Cox 1 and Cox 2 are
prescribed for the same condition, we expect the differences to be explained by the
drugs class.
in which case the increase is 33%. In the authors opinion the true increase is somewhere between
the two.
3We used a z test for differences in proportions. The p value was <0.001, both for the whole
sample, and excluding all members that could not be verified having complete pharmacy information.
4There are two additional factors that are also not the same in the two clusters, Opiates and
GI drugs. Those factors appeared frequently in clusters in a nonspecific fashion - their use was
common to many conditions. On the other hand, except for musculoskeletal clusters, the association
between anti-inflammatory drugs and medical conditions not related to the musculoskeletal system
was limited to this association with cardiac events.
5The cost has been adjusted for the cost of the Cox 1 and Cox 2 prescriptions.
Prevalence
41%
38%
34%
33%
25%
25%
24%
13%
13%
13%
Cluster 1
Description
Antihyperlipidemic drugs
Ace inhibitors & comb.
Calcium channel blockers&comb.
Hypertension
Nonsteroidal /Anti-Inflam. agent
Opiate agonists
Beta blockers & comb.
Cardiac drugs
Hypotensive agents
Antidiabetic agents, misc.
Cluster 2
Description
Antihyperlipidemic drugs
Hypertension
Ace inhibitors & comb.
Beta blockers & comb.
Chest pain
Gastrointestinal drugs
CAD
Calcium channel blockers&comb.
Diabetes mellitus
Cardiac drugs
Table 2.16: Top ten most distinguishing features of two clusters of cardiac patients.
Cluster 1 contains members that have significantly higher health care costs in the
result period compared to the observation period while Cluster 2's members have
significantly lower health care costs in the observation period. A distinguishing feature
of a cluster is a diagnosis/procedure or drug that has more prevalence among members
of the cluster than in the general population.
Cox 1 Cox 2 p-value
Number of Members 30,277 11,046
Average Cost5  $4,954 $8,306 <0.001 6
CAD Prevalence 0.05 0.09 <0.001 7
Table 2.17: Comparison of costs and cardiac outcomes in the observation period for
members taking Cox 1 and Cox 2.
6The difference in the average cost was assessed by a t test and a z test as described in [65]. Both
were significant at the p<0.001 level.
Prevalence
44%
37%
33%
31%
30%
27%
27%
23%
22%
15%
2.6 Conclusions and Future Research
The algorithms we developed based on modern data mining methods provide quan-
tifiable predictions of medical costs and represent a powerful tool for prediction of
health care costs. We also argue that R 2, that has traditionally been used to re-
port prediction accuracy has some limitations, and the use of more descriptive error
measures, specially designed for the application at hand, might give better insight
into the prediction accuracy. Despite the relative abundance of clinical information
included in our data sets, we found that for all but the highest cost patients, primary
cost information was the most accurate predictor of true costs. It is clear that cost is
an efficient surrogate for medical information, except in cases where the most dense
medical data are available. The algorithms can be used for cost predictions for indi-
viduals and groups and as a base for patient intervention in health care management.
Future research that builds on these algorithms could be used for financial reimburse-
ment/insurance pricing purposes, but such an effort requires greater integration with
health care economics, and system design.
The clustering algorithm discovered autonomously that cardiac patients taking non-
steroidal anti-inflammatory agents have higher costs in the following year. Moreover
identifies a suspected link between osteoporosis and depression The algorithm may re-
veal unexpected associations among diagnoses, procedures and drugs and may identify
potential safety issues with drugs in common use. In general, the algorithm reveals
associations, but further studies would be needed to establish causality. Effort should
also be put on automating the disocvery process, which is a current undertaking of
the author.
7The difference in the number with CAD coding was assessed by a z test.
2.A Appendix - Detailed List of Variables and Ex-
amples of Coding Groups
Table 2.1 on page 27 summarizes the variables used in our study, what follows is a
more detailed list.
1. Variables 1 thought 218 are the number of claims for a member, that have
coding belonging to different diagnosis groups. A diagnosis groups is a collection
of ICD-9 codes that have been put together to form a group. As an example,
Table 2.18 in Appendix 2.D shows all ICD-9 codes that fall into the diabetic
group.
2. Variables 219 through 398 are the number of claims for a member, that have
coding belonging to different procedure groups. These groups were created in
the same fashion as the diagnosis groups. Table 2.19 in Appendix 2.D contains
an example of all ICD-9 codes that fall into our MRI-scan group.
3. Variables 399 through 734 are the number of claims for a member, that have
coding belonging to different drug groups. The grouping is bases on the NDC
codes, and drugs from the same drug class are grouped together. Table 2.20 in
Appendix 2.D contains an example of all drugs in the Insulin group.
4. Variables 7350 through 1485 are indicators of additional specified risk factors.
We can divide the risk factors into 4 main categories:
(a) Interaction between illnesses, an example is: diabetes and obesity.
(b) Interaction between diagnosis an age, an example is: CAD and age above
65.
(c) Noncompliance to treatment an example is: a pattern of ER care without
office visits.
(d) Illness severity, an example is: diabetes with foot ulcers.
5. Variables 1486 through 1489 are counts of the number of different diagnosis,
procedures, drugs and risk factor a member has during the observation period.
6. Variables 1490 through 1511 are cost variables. Those are:
(a) Monthly costs of the last twelve months of the observation period (12
variables).
(b) Overall pharmacy costs (1 variable).
(c) Overall medical costs (1 variable).
(d) Overall cost (the sum of medical and pharmacy costs) (1 variable).
(e) Overall cost in the last 6 months of the observation period (1 variable).
(f) Overall cost in the last 3 months of the observation period (1 variable).
(g) Positive and negative trends, found by fitting a line through the last
monthly costs of the observation period (2 variables).
(h) Acute indicator, a indicator variable found by comparing the highest month
with the average monthly cost. If these are significantly different, the
indicator takes on the value 1. (1 variable)
(i) Number of months above average. This variable is an indicator of the
shape of the cost profile. If the cost is relatively constant over the period,
this variable takes on a value around six, which is an indicator for a chronic
cost profile (1 variable).
(j) The cost of the highest month in the observation period.
7. Variable 1512 is an indicator variable for the gender being female.
8. Variable 1513 is the age of the member at the beginning of the observation
period.
2.B Appendix - Classification Trees
Classification trees recursively partition the independent variable space into a set of
subspaces and assign a separate classification rule to each subspace. This partitioning
can be represented as a tree. We start with the whole sample space at a root node,
and then partition the data set into two subsets according to a splitting rule designed
to minimize a node impurity measure that has been defined. This first split is shown
in Figure 2-4. The process then continues dividing up the subspaces, until a defined
stopping criteria is satisfied.
The Whole Sample Space
Applying Spli ing Ru
Subspace 1 Subspace 2
Figure 2-4: The first step in recursive partitioning, creating the first two sub nodes.
We used the software CRUISE [2] to create our classification trees. What follow is
a discussion on some of the specifics of the algorithm, we refer the reader to [21 and
[40] for further details.
Notation
Let X be a vector of independent variables and Y be a categorical dependent variable
that takes k different values. Let t be any node in a classification tree and let Pit be
the fraction of the observations for which y = i at node t. Let Nt be the collection of
observations at node t.
Node impurity measure
The most common node impurity measure, and the one that we use, is the Gini-index,
which is defined as
k
i=1
52
which can be rewritten as
Z Pit -Pt.
isj
In the case of uneven misclassification costs, as in the case of the penalty matrix error
measure, the Gini-index is adjusted to
SW(i, j)pit pjt
isi
where W(i, j) is the cost of misclassifying as i a class j case. Note that if all the
observations belong to a single class, then the Gini-index is zero.
Splitting rule
The split is chosen to give the largest reduction in the defined node impurity mea-
sure. The split can either rely on a single variable or multiple variables. To preserve
interpretability, we choose to use single variable splits. There are two main categories
of univariate splitting methods: exhaustive search and methods that do statistical
hypothesis tests at each node to assess the significance of a split.
Loah and Shih [46] show that the key to avoiding selection bias is the separation
of variable selection from split point selection. This separation differs from the ex-
haustive search approach of simultaneously finding the variable to split on and the
splitting value. It has also been noted that exhaustive search methods are biased
toward categorical variables over numerical variables as well as toward continuous
variables over discrete variables, because the continuous variables afford more splits.
An algorithm that overcomes this bias is 1D as described in [40], where at each node
an analysis of variance (ANOVA) F-statistic is calculated for each variable. The vari-
able with the largest F-statistic is selected, and linear discriminant analysis is applied
to it to find the split value. This is the algorithm used in this chapter.
Classification rule at end nodes
At an end node, the class that minimizes a error measure is assigned to the node. For
example, for our penalty error we assign class i to an end node t if i minimizes
P(ii, y),
jENt
where P is the penalty matrix defined in Section 2.2.4 and yj is the observed class
of member j. In the case when the costs for all misclassifications are equal, the as-
signment rule simplifies to assign the most frequently observed class at an end node
as the classification rule. For the average absolute dollar error we assign the median
cost of the learning sample at each node.
Pruning and selecting the "best" tree
At some point, the recursive partitioning needs to be stopped. This stopping point
can be predefined, limited by the number of levels, minimum number of observa-
tions at a node, or when improvement in the node impurity measure is negligible. A
methodology introduced by Breiman et al. [15], which is used here, is to overgrow the
tree and then prune it back using the pruning sample. After overgrowing the tree,
the classification rule is applied to the pruning sample and the misclassification cost
is calculated at each node and at each parent node. We then cut off the nodes that
result in the smallest increase (or the biggest decrease) in the overall misclassification
cost. The result is a sequence of trees, each associated with a certain misclassifica-
tion cost. The tree with the smallest misclassification cost is called 0-SE [15]. The
smallest tree within one standard error of the minimum is called 1-SE and is the tree
we choose to use.
2.C Appendix - Clustering
This Appendix explains how the Eigencluster algorithm was adapted for medical
data mining. For details on the original version of Eigencluster we refer the reader to
[19, 38].
2.C.1 Notation and Outline
Given a learning set L and a validation set V of patients for whom we know the result
period's cost, we predict the cost for the test set T according to the below procedure.
We view each member as a vector of features, which belong in one of two categories -
cost and medical. Let Li, Vi, Ti be the subset of members in the learning, validation
and test set respectivly that belong to bucket i in the the observation period. The
procedure is as follows, and applies to any measure (the hit ratio, the penalty error,
the average absolute prediction error, etc.).
1. Define feature weights
2. Apply feature weights to Li U Vi U Ti.
3. Use EigenCluster to cluster Li U Vi U Ti based only on cost features. Let Ri be
the resulting hierarchical clustering tree.
4. Using Li, and Vi compute the frontier Fi of Ri for which clustering based on
medical information is at least as good as clustering based on cost information.
5. For each node C in Fi, let x be the single prediction that optimizes the sum of
the measure on C n (Li U Vi). Use x as a prediction for each test member in
CnT T.
Below we briefly discuss each of the outlined steps.
2.C.2 Define Feature Weights
We define two sets of weights: cost weights and medical weights. The cost weights
apply to the cost features, whereas the medical weights apply to the medical features.
As the last months of the observation period have stronger correlation with the result
period, the last months are given more weight than the first. Equal weight is given
to each of the medical features.
2.C.3 Applying Weights
For every member u (vector of features) in Li U Vi U Ti, we apply the weights ti by
setting ui +- Vwui. Thus, the inner product between members is now the weighted
similarity.
2.C.4 Using EigenCluster
The goal in applying EigenCluster is to put members who have similar cost patterns
together in a "cluster". The hypothesis is that members with similar cost patterns
in the observation period will have similar future cost patterns. In each "cluster",
there will be members of the learning, validation and test sets. Thus, we will make a
prediction for each of the members of the test set based on the result period behavior
of the learning set and validation sets.
Technical details
We apply EigenCluster to the set of members Li U Vi U Ti, where each member is only
described by cost features. The result is a hierarchical clustering tree Ri. Each node
is a subset of the members and the root node is the entire set (Li U Vi U Ti). Each
interior node has two child nodes, whose subsets comprise the subset at the parent
node. Each leaf node (a node with no child nodes) represents a subset of size at least
50.
2.C.5 Compute the Frontier
We would like to make predictions that are based on medical information, as well as
based on cost information. It appears that cost information can distinguish members
with different result period costs at a coarse level, but medical information cannot.
On the other hand, medical information can distinguish members with different result
period costs at a more fine level, whereas cost patterns cannot. This is the motivation
behind the frontier - the "coarsest" level at which medical information can distin-
guish members.
The frontier consists of nodes in R, for which we can improve the clustering us-
ing medical information, that is the resulting prediction is at least as good as if we
had clustered those nodes further using cost information. We describe next how to
compute this frontier.
Technical details
We walk up the tree Ri and apply EigenCluster to the member subset at each interior
node, but only using medical features. Suppose we are at some interior node, and
cl and c2 are the best error measures for our child nodes C1 and C2 as determined
by the learning sample (Li n Ci and Li n C2) and applied to the validation sample
(Vi n Cj and V n C2). We apply EigenCluster to the subset at our current node to
obtain a hierarchical clustering tree f. For every leaf node C in R, we compute the
single answer , that optimizes the sum of the error measure on C n Li and apply it
to the validation sample Cn Vi. Let ý be the cost incurred by J. If a, summed over
all leaf nodes is more optimal than the sum of cl and c2 , we designate this interior
node to lie on the frontier Fi, replace its subtree with R, set its cost to be the sum of
the a's and continue up R/. After we have walked up the whole tree we have replaced
parts of the tree Ri, which was built using cost information only, with number of new
subtrees 1i 's that use medical information and improve prediction.
2.C.6 Prediction
Each leaf node contains a subset of patients. Roughly two thirds are in the learning
and validation sets, and the a third are in the test set. The idea is that every member
of this node is similar - otherwise they would not be put in the same node. Therefore,
it is natural to think that the result period behavior of the patients in the learning
and validation sets is similar to the result period behavior of the patients in the test
set. This motivates our prediction technique, described below.
Technical details
We now have at our disposal leaf nodes C1,..., C,. Each C consists of members of
the learning, validation and the test sets. We compute the answers xj that optimizes
the sum of the measure on C n Li n Vi, and use this as a prediction for each member
in CnTi.
2.D Examples of Group Coding
Table 2.18
ICD-9 Code
250
2500
2500x
2501
2501x
2502
2502x
2503
2503x
2504
2504x
2505
2505x
2506
2506x
2507
2507x
2508
2508x
2509
Description
Diabetes Mellitus
Diabetes Mellitus without complications
Diabetes Mellitus without complications
Diabetes with Ketoacidosis
Diabetes with Ketoacidosis
Diabetes with Hyperosmolarity
Diabetes with Hyperosmolarity
Diabetes with Coma
Diabetes with Coma
Diabetes with Renal Manifestations
Diabetes with Renal Manifestations
Diabetes with Ophthalmic Manifestations
Diabetes with Ophthalmic Manifestations
Diabetes with Neurological Manifestations
Diabetes with Neurological Manifestations
Diabetes with Peripheral Circulatory Disorders
Diabetes with Peripheral Circulatory Disorders
Diabetes with Manifestations
Diabetic Hypoglycemia
Diabetes with Complication
Continued on next page...
Table 2.18 - Continued
ICD-9 Code
2509x
3572
3620
36201
36202
36203
36204
36205
36206
36207
36641
6480
6480x
V4585
V5391
Description
Diabetes with Complication
Polyneuropathy in Diabetes
Diabetic Retinopathy
Background Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Nonproliferative Diabetic Retinopathy
Mild Nonproliferative Diabetic Retinopathy
Moderate Nonproliferative Diabetic Retinopathy
Severe Nonproliferative Diabetic Retinopathy
Diabetic Macular Edema
Diabetic Cataract
Diabetes Mellitus - Complications of Delivery
Diabetes Mellitus - Complications of Delivery
Insulin Pump Status
Fitting/Adjust Insulin Pump
Table 2.18 An example of ICD-9 diagnosis codes in a diabetes diagnosis group ("x"
at the end of a code stands for any number.
Table 2.19
Code Description Code Origin
0159T Computer-aided detection, including computer algorithm CPT4
analysis of MRI
0160T Therapeutic repetitive transcranial magnetic stimulation CPT4
treatment pla
70336 Magnetic Image, Jaw Joint CPT4
7054x MRI of Face, Neck and Head CPT4
Continued on next page...
Table 2.19 - Continued
Code
7055x
7155x
7214x
72150
72156
7219x
73218/9
7322x
73718/9
7372x
7418x
7555x
76093
76094
76394
76400
76498
7702x
77084
C8903-8
C9723
Q0070
18891
18892
18893
Description
MRI of the Brain
MRI Chest
MRI Neck, Lumbar or Chest Spine
Magnetic Resonance (proton)
MRI (proton) of Chest, Lumbar or Angio Spine W/O&w
Dye
MRI Pelvis
MRI Upper Extremity
MRI Uppr Extremity
MRI Lower Extremity
MRI Lower Extremity
MRI Abdomen
Heart/Cardiac MRI
Magnetic Image, Breast
Magnetic Image, Both Breasts
MRI for Tissue Ablation
Magnetic Image, Bone Marrow
MRI Procedure
Magnetic resonance guidance
Magnetic resonance (eg, proton) imaging, bone marrow
blood supply
MRI , Breast
Dynamic Infrared Blood Perfusion Imaging
Magnetic Image, Spine
MRI of Brain & Brainstem
MRI Chest & Heart
MRI Spinal Canal
Continued on next page...
Code Origin
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
CPT4
HCPCS
HCPCS
HCPCS
ICD9
ICD9
ICD9
Table 2.19 - Continued
Code Description Code Origin
18894 MRI Musculoskeletal ICD9
18895 MRI Pelvis,prostate,bladder ICD9
18896 Other Intraoperative Magnetic Resonance Imaging ICD9
18897 Magnetic Resonance Image Unspecified ICD9
18899 Unspecified MRI ICD9
R483 MRI Rev Code
R61x MRI Rev Code
Table 2.19 An example of procedure codes in a procedure group. The table displays
all codes within the MRI-scan group ("x" at the end of a code stands for any number).
In general the codes in a procedure group come from various sources: ICD-9, DRG,
Rev Coding, CPT4 and HCPCS.
Table 2.20
NDC Code NDC Description RxlO0 Description
00003378015 Insulin Insulins
00069006119 Exubera Chamber Insulins
00069009741 Exubera Release Unit Insulins
00002811201 Iletin Ii Pzi Beef Insulin - Beef
00002821201 Iletin Ii Reg. Beef Insulin - Beef
00002831201 Iletin Ii Nph Beef Insulin - Beef
00002841201 Iletin Ii Lente Beef Insulin - Beef
00003244510 Insulin, Purified Ultralente Beef Insulin - Beef
00169352215 Insulin Standard Nph Insulin - Beef
00169352815 Insulin Standard Lente Insulin - Beef
00169357805 Insulin Standard Semilente Insulin - Beef
00169357215 Insulin Standard Ultralente Insulin - Beef
Continued on next page...
Table 2.20 - Continued
NDC Code NDC Description Rx10O Description
00002811101
00002821101
00002831101
00002841101
00002850001
00003244110
00169010001
00169020001
00169030001
00169244010
00169244210
00169244710
00169351215
54569165200
54569165202
54569281600
54569281700
54569289100
54569289101
00002811001
00002824001
00002831001
00002844001
00002851001
00002864001
54569165101
54569165102
Iletin Ii Pzi Pork
Iletin Ii Regular Pork
Iletin Ii Nph Pork
Iletin Ii Lente Pork
Iletin Ii Regular Pork
Insulin, Purified Semilente Pork
Insulin Purified
Insulin Purified
Insulin Purified
Insulin Purified Regular Pork
Insulin Purified Lente Pork
Insulin Purified Nph Pork
Insulin Standard Regular
Iletin Ii Reg. Pork
Iletin Ii Reg. Pork
Insulin Purified Lente Pork
Insulin Purified Regular Pork
Iletin Pork Nph
Iletin Pork Nph
Iletin Pzi
Iletin Regular I
Iletin Nph I
Iletin Lente I
Iletin Semilente
Iletin Ultralente
Iletin Nph I
Iletin Nph I
Continued on next page...
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Insulin
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Beef
Beef
Beef
Beef
Beef
Beef
Beef
Beef
Pork
Pork
Pork
Pork
Pork
Pork
Pork
Pork
--------
Table 2.20 - Continued
NDC Code NDC Description RxlO Description
54569295100 Iletin Regular I Insulin - Beef & Pork
54569295101 Iletin Regular I Insulin - Beef & Pork
54868142801 Iletin Nph I Insulin - Beef & Pork
54868208901 Iletin Regular I Insulin - Beef & Pork
00002751001 Humalog Insulin - Human
00002751101 Humalog Mix 75/25 Insulin - Human
00002751559 Humalog Insulin - Human
00002751659 Humalog Insulin - Human
00002821501 Humulin R Insulin - Human
00002821601 Humulin Br Insulin - Human
68115083910 Lantus Insulin - Human
Table 2.20 An example of drugs in a drug group. The table contains examples of
drugs that belong to the Insulin group, as well as their NDC codes.

Chapter 3
Drug Surveillance
The Food and Drug Administration is responsible for the evaluation of new drugs.
A large part of their role is to ensure drug safety. After a drug is approved (if the
FDA approves it as safe and effective), the drug maker is responsible for reporting
any adverse drug events it learns of to the FDA. In addition, the FDA runs a post-
FDA-approval drug surveillance system called the Adverse Event Reporting System
(AERS), which is a voluntary system in which patients and health care professionals
can submit reports of adverse events. Although the system has often proved useful
in identifying serious side effects of drugs, it has been insufficient in identifying po-
tential safety signals, especially since events that can be indicators of increased risk
of common conditions might not be considered important by individual patients or
health care professionals.
A safety concern raised through the AERS system, or through different channels
such as the medical literature, results in warnings to consumers or in serious cases
a withdrawal of the drug. A black box warning is the strongest warning the FDA
can require. The warning appears on the package insert in a black box stating that a
drug can potentially have serious or life-threatening adverse effects. Among some of
the more widely covered warnings in recent years are the following:
e The FDA has required that black box warnings be placed on all antidepressant
medications stating they may result in increased risk of suicidal tendencies in
children and adolescents.
* FDA advisors have recommended that Pfizer be required to place a black box
warning on their Non-Steriodal Anti-Inflammatory (NSAID) drug celecoxib
(U.S. trade name Celebrex).
* In November 2004, the FDA required a black box warning on the Depo-Provera
contraceptive injection, due to the risk of significant loss of bone density with
long-term use.
* In October 2006, the FDA added a black box warning to the anticoagulant
warfarin due to the risk of bleeding to death.
* In November 2007, the FDA added a black box warning to the diabetes medi-
cation Avandia, citing the risk of heart failure or heart attack to patients with
underlying heart disease, or those at a high risk for heart attack.
After the withdrawal of rofecoxib (known outside the medical profession under the
marketing name of Vioxx) from the pharmaceutical market in 2004, post-FDA-approval
drug safety and surveillance has come under serious scrutiny. A 2006 study by the
Institute of Medicine pointed out that efforts to monitor risk-benefits tradeoff of med-
ications decrease after FDA approval and that this issue needs to be addressed [55].
Large claims databases, with near-real time1 information coupled with advanced sta-
tistical models have the potential to greatly improve post-approval drug surveillance,
by analyzing individual outcomes in a very large population. Events that on individ-
ual level might not look significant (and therefore not get reported to the AERS) can
be serious risk indicators when aggregated over large populations. Such approaches
can not only discover side effects but also potential added benefits.
10One can expect about a three month delay for claims processing and data processing.
3.1 Previous Work
To the best of our knowledge, there is not a large literature on real-time drug surveil-
lance. The most recent [16] is the first paper to attempt detection of adverse drug
events within a population as a function of time, using claims data. The major draw-
back of the paper is that the authors do not test across all possible adverse events,
but rather just for a single known side effect and one other effect as a control. They
successfully show that adverse events can be detected. Moreover, studies have also
started to analyze what a post-marketing surveillance system should entail [11]. A
couple of studies focus on vaccine surveillance and monitoring of the vaccines known
side effects. The most recent study [45] uses maximized sequential probability ratio
testing to test for known side effects, the same method is used in the most recent
drug surveillance study [16].
Numerous studies use claims data to investigate drug effects. [34], led one of its
authors to testify before the US Senate in the rofecoxib case, as the study drew at-
tention to how much and when the FDA knew about the increased cardiac risk for
patients taking rofecoxib. That study and others [58, 33] demonstrate that claims
data can be an effective means to monitor drugs and their side effects.
3.2 Overview, Terminology and Notation
According to the FDA's Orange book [7], over 2000 different (or different combinations
of) approved pharmaceuticals are marketed under over 5500 different names. Many
of the drugs are commonly used, while others are rarely found in claims databases.
In this thesis we focus our attention to drugs in common use, although much of the
methodology is transferable to less common drugs (in some cases more direct meth-
ods, such as randomized trials, may be more appropriate). We choose to focus on
these drugs as they play to the strength of claims data, its near immediate availabil-
ity and large size, which allows us to detect changes in occurrences of rare events,
relatively fast.
Drugs are most commonly prescribed for a single reason or diagnosis. Often there
is a choice of more than one drug to treat the condition; for example, atorvastatin
(marketed under the name Lipitor) and simvastatin (marketed under the name Zo-
cor) are both drugs that treat high cholesterol. These drugs are very similar [66], and
there are no clinical reasons why a doctor would prescribe one over the other2 . In
this case, we can compare populations on one drug to populations taking another. If
a drug has quickly become the treatment of choice, a comparison group might not
be available, as similarly sick members are not being treated without the drug. With
access to older data, we can build a comparison group from previously treated pa-
tients and compare the outcomes of similar patients who were treated before the new
drug became popular. Care needs to taken to make sure that changes in coding be-
havior do not affect the outcome, but the same methodology applies. In this chapter
we propose different methods to adjust for differences in populations and suggest a
methodology to compare the two populations once selected.
We will call the members taking the drug of interest a treatment group, and the
group of members that we compare them with the control group. The exposure of a
member to a drug, is the time a member is taking the drug. An adverse event can
be an onset of a disease such as asthma or a single event, for instance stroke. We
define adverse events in terms of the members' claims data, for example by counting
the number of claims associated with a particular adverse event. We define the post-
toxicity time period as the time after a member stops taking a treatment drug until
its toxicity no longer affects him or her, which varies from drug to drug.
We consider one-month time intervals, as that is the most common rate of claims
2The main clinical advantage of atorvastatin over simvastatin is that it is not metabolized by
certain liver enzymes, and thus its blood concentration is not increased when combined with grape-
fruit juice which inhibits these enzymes. Simvastatin patients should therefore avoid drinking large
amounts of grapefruit juice for this reason.
data updates. We define pi as the probability that an adverse event i happens in any
particular month, for any member.
3.3 Selecting Comparison Populations
When we compare effects of a drug, we need to select a comparison population to
serve as a baseline. Ideally this population is very similar to the treatment popula-
tion in terms of age, gender, disease burden and other important factors for medi-
cal outcomes. Carefully choosing the comparison group is vital to an efficient drug
surveillance system, as a wrong baseline will result in a drift away from the expected
number of events, resulting in multiple false alarms. When there is an alternative
drug given for the same condition as the treatment drug in question, such as in the
case of simvastatin and atorvastatin, the two populations are very similar and can
possibly be used without further adjustments. In other cases adjustments are needed.
Below we discuss methods for making the adjustments.
3.3.1 General Methods
When a similar drug to the one under study is on the market, but the groups do not
fully overlap (for example, in the case of rofecoxib and naproxen; naproxen is more
common in children than rofecoxib), simple adjustment methods can be used to select
the comparison population. These include
* Randomly select members from the comparison population so that the age and
gender (and even cost-bucket) distribution is similar.
* Estimate the baseline rates for each of the sub-populations and combine them
in an estimate reflecting the age and gender (and cost) distribution of the treat-
ment population.
Section 3.7 reports on how these methods work with real data. Previously, researchers
have used comorbidity-scores and propensity-scores to adjust for differences in the two
populations. We found the simple selection methods mentioned above to be more
successful, in our experiments.
3.3.2 Maximal Pairing
Perhaps the most accurate way to select a comparison group is to select, for each
member in the treatment group, a member (or members) in the control group with
very similar pre-treatment medical history and conditions. To do so, we can solve a
maximum (multiple) pairing optimization problem, in which constraints are placed on
age, gender, important conditions and risk factors as well as overall medical similarity.
We propose the following formulation to measure medical similarity. Let xi(t) be
a vector of medical features (diagnosis, procedures and drugs) for member i, at time
t. In particular let ij (t) be the number of days with claims that include code (or code
group) j, for some pre-specified time prior to starting on a drug. Let w be a weight
vector, that weights the features to account for different importance of different codes.
For example, we place a greater weight on cancer conditions than on a common cold,
or a routine doctor's visit. We define a rescaled vector fi(t) for member i as:
w'xzi(t)V(t) = -x (t)
and the medical similarity of any two members as the inner product of their rescaled
vectors. This way, the weighted medical similarity of a member with himself is one
and the weighted similarity between any two members i and k is between zero and one.
We can now write a standard optimization problem, that will maximize the num-
ber of control-treatment member pairs in the study. Let Yik be an indicator variable
that equals one if members i and k being paired up for the study, and is zero otherwise.
The standard maximum pairing problem is then written as,
maximize Z Z Yik
i k
subject to Yik 1 for all i
k
Z Yik 1 for all k
Yik E {0, 1} for all i and k.
To reduce the size of the problem (recall that our treatment and control populations
might be on the order of 100,000, and therefore the number of possible pairs of the
order of 100,0002) we include only those Yik in the input that satisfy the medical
similarity constraints, as well as age, gender and risk factor requirements. The for-
mulation can easily be extended to allow for multiple control members to be paired
with a treatment member.
One of the major drawbacks of the method, is that it cuts down on the number
of members that can be used for the study significantly, especially if the population
is on the smaller side (as the probability of a similar member being found in the
control group is smaller). We can relax the formulation by matching members only
based on known risk factors for a given condition for example age, gender, hyperten-
sion, cholesterol drugs and diabetes in the case of cardiac events (this would result in
solving multiple optimization problems, one for each condition under surveillance).
Considerations when a Similar Drug does not Exist
If a similar drug exists, the medical feature vector for a member on the comparison
drug has a natural "anchor" date, the day he or she starts the comparison treatment.
The medical feature vector can then be built from the data over the pre-specified
period prior to starting treatment. When no comparison drug exists, we need to define
a fixed date, to use as "anchor" date for the comparison population, to avoid biases
in the selection process. This date can be some time (T) in the past, which has the
added benefit that we already know the post-treatment outcomes for the comparison
population. Knowing the outcomes for the comparison populations results in a more
stable baseline. In contrast, selecting T as the present, we would be following two
random processes, the outcomes of the treatment members on one hand and the
control members on the other. This would cause more fluctuation in the estimated
baseline rates.
3.3.3 Population Maximization
The idea is to select the largest comparison group possible that is similar (pre-
treatment) to the treatment group, with the goal of finding stable baseline estimates.
Below we assume a similar drug exists and refer the reader to the end of Section 3.3.2
for considerations when building the data vectors in the absence of a similar drug.
Let xi be a decision variable, indicating whether or not member i of the control
group is included in the study. Let aij be the value for condition j for member i. In
each month we would solve the following optimization problem
maximize xi
subject to aijxi - (aj + 6j) x i 0 for all j
i i (3.1)
- aiji + (aj -6) xi > 0 for all j
i i
xi E {0, 1},
where •j is the average diagnosis value for the treatment group for control j and 5j
is the allowed perturbation around it. The controls can include cost, age, gender,
disease burden, average lenght of pre-treatment history, average time on drug, etc.
From the chosen comparison group, which is similar to the treatment group prior to
drug use, we then estimate the baselines for different outcomes.
Beyond Averages
One of the pitfalls of this formulation is that it takes into account only the average,
which means the distribution of a control can be quite different between the two
groups. (An extreme example would be one population with very young and very
old members, and the other with only middle-aged members, both groups could have
the same average age.) We can account for these differences by constraining controls
over subgroups. For example, we can require the same fraction of the population to
be under the age of b. Let fb be the fraction of members under b in the treatment
group. Then by adding the constraints
E xi-(fb+6b) i < 0 and
ilagei<b i
- S + (fb - 6b) xi 0O
ilagei<b i
we make sure that the fraction of members under b in the comparison group is within
6 b of the treatment group. In general, we can constraint the average of a subpopulation
(Sk) to be between ajk ± 6jk by adding
E aijxi- (ajk + kj) i X 0 and
ieSk ieSk
- aijxi + (ayk - 6kj) E Xi < 0,
iESk iESk
to the formulation. This formulation therefore has flexibility in terms of the restric-
tions it can place on the comparison population.
Accounting for Better General Health
When one population is generally healthier than the other, as we will see is the case
of rofecoxib and naproxen, the optimal solution to (3.1) will tend to have the lower
bounds of the diagnosis condition constraints tight. Therefore, the comparison popu-
lation will be on average healthier across most if not all code groups compared to the
treatment population. We can address this problem by introducing new constraints
that ensure that only fraction of the conditions in question can be lower for the com-
parison compared to the treatment population. We suggest two ways to achieve this
objective. First, we can sum up over all the conditions, the differences between the
target disease burden (of the treatment group) and the actual disease burden of the
comparison group and set the sum to approximately zero. Mathematically, we can
write this relaxation as
S- o+ tand
i i
j i (xi±) I
where all data has been re-scaled to the same mean and standard deviation, 7j is the
rescaled average value for diagnosis j for the treatment population, dij is the rescaled
data value of diagnosis j for the comparison population member i, and finally 6 tot is
the flexibility we allow in the overall health.
Another approach to even the disease burden is to add additional variables to the
formulation to limit the number of conditions that have higher (or lower) average
values for the comparison population compared to the treatment group averages. To
achieve this, we introduce new variables and rewrite (3.1) as
maximize zi
subject to C aijxi - (aj + Jj - bjyjL) i '5 0 for all j
i i
- aijxi + (oi - 6j + Jjyju) xi < 0 forallj
SYjL > kL
i
Yju > kuŽ
YjL, jU E {0, 1},
where kL is the number of conditions we want to ensure that the comparison popu-
lation has at least the same prevalence (or higher) when compared to the treatment
population and ku is the number of conditions we want to ensure that the comparison
population has at most (or lower) prevalence of the disease than the treatment group.
3.3.4 Not Adjusting the Population
So far we have discussed methods for selecting a comparison group, so that pre-
treatment, the populations have the same characteristics. Another approach is not
to adjust the comparison group at all. Instead of applying often complicated selec-
tion methods, we simply observe the two populations independently and analyze the
changes. The intuition is that if the drug has no effect, the underlying rate of adverse
events should not change, and the before and after rates should be similar. Monitor-
ing the comparison group at the same time has the added benefit of accounting for
the effect of the underlying disease as well as possible coding changes. Section 3.5
discusses how to monitor drugs without a direct comparison baseline.
3.4 Mathematical Modeling of Surveillance Sys-
tem with a Comparison Group Baseline
We use the comparison group to estimate the probability pi of an adverse event i
occurring for a member in any given month. This estimated probability serves as a
baseline for the treatment population. If we view the population as a homogenous
population, then the expected number of events in a particular month t for a treat-
ment population of size n is n - pi. Assuming that events in different months are
independent, then the sum of events i over 7 months is a binomial random variable:
Bin(Et~1 n(t), pi), where n(t) is the number of members in the treatment population
in month t.
We can reject the null hypothesis that the probability of an event equals pi if the
number of observed events falls far enough from N, = E• • n(t) . pi, the expected
number of events. In particular, for some significant level (1-a), we reject the null
hypothesis if N, falls outside the (smallest possible) interval [kl, k2] defined by
max P(k < ki) < a/2,
kl
max P(k > k2) > a/2,k2
where k is Bin(ELt=Z n(t), pi).
When n is sufficiently large and
Pi -n _n -pi . (1 -pi)
we can approximate the binomial distribution with a Poisson distribution and build
confidence intervals in the same way.
3.4.1 Poisson Approximation for Non-Homogeneous Groups
Very commonly, adverse events for example heart attacks vary greatly with both
gender and age (as well as underlying health status). Therefore, the probability pi
of an event i occurring is not uniform over the group. To overcome this problem, we
divide the population into subgroups. In particular if j is a subgroup of the population
with nj members and
Pij " nj nj , Pij (1 - pij )
holds for all subgroups j = 1, ... , J, then the number of events up to time t has
an approximate Poisson distribution, and the expected number of events up to and
including T is equal to
SJ
E 5P ij " nj(t).
t=1 j=1
At any point in time we can therefore draw a (1-a)% confidence interval around the
expected mean and reject the null hypothesis of the rates of adverse events being the
same if the observed number of events is far enough from our expected number.
3.4.2 Controlling for False Positives
So far we have not taken into account that we are looking at multiple possible adverse
events at the same time and therefore putting ourselves at risk for false positives. If
we have defined M possible adverse events, at any point in time we expect M -a to
be outside the confidence intervals (prior to observing any data), in the absence of
any true effect of the treatment. We also need to keep in mind that conditions are
not independent. For example, a member who gets a lung infection is more likely to
get asthma, making controlling for false positives even more important.
When some Ni(t) > Ui(t), where Ui(t) is the upper (1 - a/2) % confidence inter-
val, there is the possibility that we have observed this increased rate by chance alone.
Below we list how this issue can be addressed.
1. We can make a very small, or choose a such that we optimize the tradeoff
between the number of false positives and the detection of side effects.
2. We can start a new process that includes only new members (members starting
on the drug) to avoid any biases and monitor this new process. This approach
has the serious drawback of cutting down the population and could result in a
very long additional ramp-up time while building up a new population.
3. We can continue to monitor the same process but define a new target A and
target time T (based on the Poisson distribution). We accept the diagnosis as a
side effect, only if the number of additional events reaches A on or before time
T.
In our case studies we chose the third option, as our data did not allow us the luxury
of restarting the process, and the third option has a lower false positive rate than the
first option, when the time to discovery of a true signal is kept constant.
Medical coding is constantly changing, and medicine is often complex. Coding pat-
terns change when reimbursement policies change. This change can affect the baseline
estimates (especially those that are estimated from historical data). A two-step sys-
tem allows for flexibility to investigate potential explanations behind the increase at
the time of first alert, both systematic changes in coding behavior and undiscovered
underlying explanatory variables for the conditions: even though we have selected a
"similar" comparison group, for rare events there might be a underlying reason that
is missed in the process.
3.5 Mathematical Modeling of Surveillance Sys-
tem without a Comparison Group Baseline
Section 3.4 discussed how to compare a treatment population to a comparison pop-
ulation, when the comparison population is selected to be similar to the treatment
group. A different approach is to not adjust the comparison population prior to mon-
itoring the drugs, rather accept that they may be dissimilar and follow the changes
for the two groups independently. We assume that the comparison group is large, and
therefore the observed rates of the comparison population can be considered known
and constant. We therefore want to monitor the change in the adverse event rate and
to detect if a) it significantly increases and b) the relative change significantly differs
from the change in the comparison group.
Let pcb(i) and pa(i) be the before- and after-treatment probabilities for adverse event
i for the comparison group (assumed non-random), and let ptb(i) and pta(i) be defined
similarly for the treatment group. We want to raise a safety concern, if we observe
that Ptb(i) < Pta(i) and that the relative change3 is greater for the treatment group
than the control group, that is
Pca(i) - Pcb(i) Pta(i Ptb(i)
Pcb(i) Ptb(i)
Equivalently,
Pta (i) - ptb(i) > Pca(i) - pcb(i)
Ptb(i) Pcb(i)
Pta(i 1> c(i) 1
Ptb(i) Pcb(i)
ptW(i > pca(iW
Ptb(i) P- cb(i)
The resulting hypothesis test of the relative change for the treatment population
being greater than that of the comparison population results in a chi-square test with
one degree of freedom [14, 28]. As before we compare our outcomes to an upper
(1 - a/2)% confidence interval. We note that the confidence interval depends on
Ptb(i) and Pta(i), which are both a function of the size of the treatment population
and the prevalence of the event.
3We chose to use relative change rather than absolute change, as the starting probabilities
(Pcb(i), Ptb(i)) might be quite different and make a direct comparison difficult.
3.6 Practical Considerations
3.6.1 Time on Drug and Toxicity Period
The literature [16] suggests that the minimum time that a member needs to take
the drug and the definition of the post-toxicity period are very important. Our case
studies, however, show that the minimum time a member takes a drug is in many cases
not important, and the trade-off of having a larger population by having the minimum
time shorter (even down to a single prescription) makes including everyone preferable.
We illustrate this point in our rofecoxib case study in Section 3.7. Intuitively, one
expects the toxicity of a drug to go down as time passes after a member stops taking
the drug. The exception to this phenomenon occurs when a permanent damage has
been done. Due to limitations on the size of the data set, we were unable to research
the effects of varying the post-toxicity period.
3.6.2 Definitions of Events
We define events using the occurrences of specific ICD-9 codes in the claims data. An
event can be defined in a number of different ways.
* Claim-line event: Each claim line (a data entry) with the particular diagnosis
code of interest is an event. This definition can result in multiple counts per
days, if a diagnosis is associated with multiple procedures or financial transac-
tions. This count can be useful as it is an indicator of the severity of the event,
but on the other hand it introduces a lot of variability into the parameter esti-
mates.
* Claims-day event: Each day that a diagnostic code appears in the data defines
an event.
* Claims-period event: This event is defined as a period of time within which
all occurrences of the code count as a single event. Claims-period event is
parameterized by the number of consecutive days d without the diagnosis code
allowed, without ending the event. As an example, if d = 5 then a single event
can have a 5 day long break in coding, if there are 6 or more days before a code
reappears in the claims data, then the reappearance counts as a new event. It
is natural to allow for some break in coding, as in many clinical cases there may
be follow-up appointments, prescriptions to be filed or long-term treatment.
If d = 0, the claims-period event definition becomes the claims-day event. If
d = T, where T is the study horizon, the claims-period event becomes a count
of first occurrences of conditions.
It is important to note that for some adverse effects, such as heart attacks, the way
an event is defined has very little effect on drug surveillance. On the other hand, for
other diseases it can be misleading to define events in certain ways. This difference
depends on the nature of the events in question. Some events are a "one time thing,"
such as complications of labor; others may take a long time to resolve (resulting in
multiple claims over a long period); finally, some events can be the start of a long
and irreversible condition, such as the onset of Alzheimer's disease. The definition of
events may therefore not be the same for every diagnosis.
3.6.3 Grouping of Codes
The ICD-9 codes are organized in a hierarchical structure, by the organ systems. One
can view the structure as a tree, and every level of the tree represents an additional
digit of the ICD-9 code, and the descriptions of the conditions get correspondingly
more detailed. There is a significant variability in ICD-9 coding, as some health care
professionals may code only to the third digit, while others to the fourth or fifth.
At the same time, the further down the tree, the less common the conditions get,
and therefore the harder it is to observe a significant shift in risk. Lastly, sometimes
neighboring codes (that have the same parent) are very similar and can be joined
into one for the purpose of drug surveillance. All these considerations should be
taken into account when a drug surveillance system is implemented, and medically
trained professionals who are knowledgeable about the codes are needed to construct
a good code grouping at the right coding level.
3.6.4 Stability of the Estimates
When surveiling a new drug, it takes a while to observe enough events to get a
stable estimates. This is particularly true when we follow the relative change. We
therefore need to wait until we have observed enough events to be able to raise a
flag with some confidence. We define A(e,(t)) as the maximum fluctuation allowed
in a estimator over the past 7 months at time t, before a flag can be raised. In our
numerical experiments, we have found that defining A(el(t)), A(e2(t)), A(e 3(t)), the
change over the past one, two and three months to work well (using a single A(e,(t))
allows for unwanted conditions to slip through).
3.7 Case Study: Rofecoxib and Naproxen
Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID)4 developed by Merck
& Co. to treat osteoarthritis, acute pain conditions, and dysmenorrhoea. Rofecoxib
was approved FDA on May 20, 1999 and was subsequently marketed under the brand
names Vioxx, Ceoxx and Ceeoxx.
In November 2000, the New England Journal of Medicine published the VIGOR
(Vioxx GI Outcomes Research) study [13]. The goal of the study was to assess
whether rofecoxib is associated with a lower incidence of upper gastrointestinal events
when compared to naproxen. The study showed reduced gastrointestinal events for
the rofecoxib population, but also reported a four-fold increase in cardiac events.
This increase, however, was deemed not statistically significant and attributed to a
positive effect of naproxen. The results of the VIGOR study were submitted to the
4Nonsteroidal anti-inflammatory drugs (NSAIDs) come in two classes, non-selective COX-1 and
selective COX-2. COX-1 mediates the synthesis of prostaglandins responsible for protection of
the stomach lining, while COX-2 mediates the synthesis of prostaglandins responsible for pain and
inflammation. The COX-2 therefore delivered the same pain relief, but with reduced risk of peptic
ulcers.
FDA in February 2001, which led to the introduction of warnings on rofecoxib label-
ing concerning the increased risk of cardiovascular events (heart attack and stroke)
in April 2002.
In October 2001, another study [42] was published that compared rofexocib to a
placebo. This study found an elevated death rate among rofecoxib patients, although
the deaths were not generally heart-related. However, the study did not find any
elevated cardiovascular risk due to rofecoxib. Before 2004, Merck cited this study
as evidence of rofecoxib's safety, contrary to VIGOR. In the following months, more
studies and articles appeared [17, 51], and researchers debated the cardiac side effects
of rofecoxib. Around the same time, another study [58] demonstrated the protective
cardiac effects of naproxen compared to other NSAIDs.
In 2001, Merck started the APPROVe study, a three-year trial with the primary
aim of evaluating the efficacy of rofecoxib for the prophylaxis of colorectal polyps.
The APPROVe study was terminated in 2004, when the preliminary data from the
study showed an increased relative risk of adverse cardiovascular events (including
heart attack and stroke) beginning after 18 months of rofecoxib therapy. At the same
time, information about an FDA study [34] that supported previous findings of in-
creased risk of heart attack due to rofecoxib came out. The study estimated that
rofecoxib caused between 88,000 and 139,000 heart attacks, 30 to 40 percent of which
were probably fatal, in the five years the drug was on the market.
On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market be-
cause of concerns about the increased risk of heart attack. Rofecoxib was one of the
most widely used drugs ever to be withdrawn from the market. In the year before
withdrawal, Merck had sales revenue of $2.5 billion from rofecoxib.
The goal of this case study is to assess whether an active drug surveillance system
could have led to faster withdrawal of rofecoxib from the market.
3.7.1 The Data Set
The data set used in this study contains claims from close to 2.4 million members
between 5/1/1999 and 12/1/2005. Most members are active during only a fraction
of this period, and the data contains a total of 33,215,756 member months. We have
a total of 24,044 members who were prescribed rofecoxib and 71,100 members who
took naproxen. The average time in the data set prior to treatment is 12.9 months
for the naproxen members and 9.7 months for the rofecoxib members.
As in the previous chapter, the data is acquired through D2Hawkeye. D2Hawkeye is
a growing company founded in 2001, and therefore very little data is available from
the early years of rofecoxib. The first prescription for rofecoxcib in our data set is in
early July 2000. Figure 3-1 shows the number of members starting on rofecoxib each
month, the number of members stopping each month, the overall number of members
taking rofecoxib each month, and the cumulative number of members who have at
some point taken the drug. The sharp increase in number of members starting on
rofecoxib about 30 months into the study is explained by new clients being acquired
by D2Hawkeye.
Days on drug
Table 3.1 show the number of days a member is on the drug (assuming that he or
she takes all her dispensed medication). As we can see, close to half of the rofecoxib
members take rofecoxib for 30 days or less. Therefore in this case study, we cannot
be too stringent about the minimum time a member takes the drug. Section 3.7.4
shows how varying the minimum requirement affects the results of the study.
Given the late adoption of rofecoxib in this data set and the short period of time
members stay on rofecoxib, we choose to set the toxicity period to the length of a
member's stay in the database. Restricting the toxicity period to be a fixed time
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Figure 3-1: The top-left figure shows the number of members starting rofecoxib each
month; the top-right figure the number of members who stop taking rofecoxib. The
bottom-left figure shows the number of active members at each point in time and
finally the bottom-right picture shows the cumulative number of members who have
ever taken rofecoxib in our data set. The x-axis represents the number of months
from the start of the study (July 2000).
period would cut down our data set too fast, and as a result we would lose the ability
to detect rare adverse events.
Age and Gender Distribution
When we compare the rofecoxib population and the naproxen population, we find that
the average age differs by 9 years: it is close to 40 years for the naproxen population,
and 49 years for those taking rofecoxib. Naproxen is more prominent among women
and children, as Table 3.2 shows. We define the following age groups that we use
throughout the study: 1) 0-19 years old, 2) 20-30 years old, 3) 30-34 years old, 4)
35-39 years old, 5) 40-44 years old, 6) 45-49 years old, 7) 50-54 years old 8) 55-59
Number Starting Vioxx
,,,,^L1
20 40
^^^^
... '''
Days on Drug Rofecoxib Naproxen
0-10 2,957 19,989
11-30 8,767 35,083
31-60 2,974 8,501
61-90 1,987 2,862
91-120 1,092 1,444
121-150 757 716
151-180 954 648
181-210 491 361
221-240 416 298
241-270 610 227
271-300 290 206
301-330 226 145
331-360 382 199
more 2,055 961
Table 3.1: Length of naproxen and rofecoxib therapy.
years old, 9) 60-64 years old, and 10) over 64 years of age.
Naproxen Rofecoxib
Age Group Male Female Male Female
1 3.0% 4.9% 0.9% 1.1%
2 5.1% 9.2% 2.3% 3.3%
3 3.9% 6.3% 2.4% 2.9%
4 4.6% 6.9% 3.4% 4.5%
5 5.2% 7.9% 4.9% 6.4%
6 5.2% 8.0% 6.1% 8.7%
7 4.6% 6.5% 6.3% 9.6%
8 3.4% 4.6% 6.0% 9.0%
9 2.0% 2.5% 4.4% 6.5%
10 2.7% 3.5% 4.7% 6.6%
Table 3.2: The age-gender distribution of rofecoxib and naproxen members.
Pre-treatment Costs and Diagnosis
Since naproxen and rofecoxib were approved for treatment of the same conditions,
one would expect the populations prior to starting the treatments to be similar. The
data, however, tell a different story. Table 3.3 shows the average monthly health
care cost prior to starting treatment, by age group. We note that the rofecoxib
members uniformly have higher pre-treatment costs. The 300% cost difference in the
lowest age group is in part explained by the fact that the average age in age group
1 for naproxen is lower than for rofecoxib. Table 3.4 shows the average number of
claim-line events per month for seven randomly chosen diseases. We note that for
6 out of 7 diseases the prevalence is higher for the rofecoxib population. In fact,
"thyroid problems" is one of the few diagnoses that is virtually equal between the
two populations. These differences are only in small part explained by the difference
in age-gender distribution, as verified by a more detailed analysis.
Age Group Naproxen Rofecoxib Difference
1 $132 $527 299.1%
2 $195 $281 44.2%
3 $224 $365 62.5%
4 $219 $358 63.9%
5 $224 $376 67.8%
6 $243 $319 31.2%
7 $279 $397 42.1%
8 $312 $403 29.1%
9 $348 $477 37.1%
10 $225 $414 83.8%
Table 3.3: Comparison of pre-treatment costs. The second and third columns show
the average cost per month before starting treatment of naproxen and rofecoxib,
respectively.
Disease Naproxen Rofecoxib Difference
Anemia 0.0058 0.0083 44%
Benign Neoplasms 0.0103 0.0119 16%
Endocrine 0.0450 0.0548 22%
Malignant Neoplasms in Bone 0.0056 0.0139 150%
Nutritional Deficiencies 0.0005 0.0010 104%
Other Blood Diseases 0.0015 0.0043 177%
Thyroid 0.0103 0.0102 0%
Table 3.4: Comparison of pre-treatment diagnosis prevalence. The second and third
columns show the average number of claim-line events per month before starting
treatment of naproxen and rofecoxib, respectively.
3.7.2 Event Definitions and Code Grouping
As previously mentioned, the ICD-9 codes are structured in a hierarchical way. Due
to coding inaccuracies at the lower levels, we chose to focus on three-digit codes
(including all subsequent four- and five-digit codes). We furthermore merge codes
that have the same parent code and represent the same condition. As an example,
we group together all tuberculosis codes, which all fall under the parent category of
infectious and parasitic diseases. Table 3.5 shows the eight different level-3 codes for
tuberculosis. Details of the group coding appear in Appendix 3.A. Tables 3.6 and
3.7 summarize the codes used for identifying the two known side effects of rofecoxib
at the time of withdrawal, heart attacks and stroke.
ICD-9 Code Description
010 Primary tuberculosis infection
011 Pulmonary tuberculosis
012 Other respiratory tuberculosis
013 Tuberculosis of meninges and central nervous system
014 Tuberculosis of intestines, peritoneum, and mesenteric glands
015 Tuberculosis of bones and joints
016 Tuberculosis of genitourinary system
017 Tuberculosis of other organs
018 Miliary tuberculosis
Table 3.5: Level 3 ICD-9 codes grouped together in the tuberculosis group, a part of
infections and parasitic diseases.
ICD-9 Code Description
410 Acute myocardial infarction
411 Other acute and subacute forms of ischemic heart disease
4110 Postmyocardial infarction syndrome
4118 Other
41189 Other
4130 Angina decubitus
Table 3.6: ICD-9 coding used to identify heart attacks.
ICD-9 Code Description
433 Occlusion and stenosis of precerebral arteries including basilar
artery, carotid artery, and vertebral artery, etc.
434 Occlusion of cerebral arteries including cerebral thrombosis and cere-
bral embolism and unspecified cerebral artery occlusion.
435 Transient cerebral ischemia
Table 3.7: ICD-9 coding used to identify strokes.
3.7.3 Using Optimization to Select the Comparison Groups
In our research we implemented all of the strategies discussed in Section 3.3. Our
observations on using optimization methods appear below, and Sections 3.7.4 and
3.7.5 reports the results of other methods.
Using Maximum Pairing
Pairing each rofecoxib member with a naproxen member based on their medical his-
tories prior to starting the treatment results in data samples that are very similar.
We implemented this approach but found it to be unsuccessful due to how fast it
cuts down on the data. To be able to compute members' similarity, we need at least
6 months of data prior to starting treatment, for each member. This criterion ex-
cludes 27,727 naproxen and 11,892 rofecoxib members from the study; we lose almost
half of our rofecoxib population. The minimum number of days on a drug and other
inclusion requirements leave very few members in the sample. Table 3.8 shows the
number of potential members to be paired up in each month for two years, from May
2001 to May 2003, when we required at least 90 days of taking the drug and at least
180 days in the sample before and after the start of treatment. In the optimization,
age and gender were ignored, and minimum similarity was set to the average simi-
larity of members. This combination of rather stringent inclusion criteria but loose
optimization criteria results in zero observed cardiac events over the two year period.
We therefore conclude that although matching based on past history would take care
of all discrepancies in the pre-treatment disease burden, due to the limited number
of members that have sufficient prior history in our data set, this method was unsuc-
cessful. This method may potentially work better with larger data sets that include
more members over longer periods.
Month
May 2001
June 2001
July 2001
August 2001
September 2001
October 2001
November 2001
December 2001
January 2002
February 2002
March 2002
April 2002
May 2002
June 2002
July 2002
August 2002
September 2002
October 2002
November 2002
December 2002
January 2003
February 2003
March 2003
April 2003
May 2003
Table 3.8: The number of potential members for pairing.
Using Population Maximization
As opposed to trying to match every single rofecoxib member with a similar naproxen
member, population maximization tries to adjust for the pre-treatment disease bur-
den over the whole population at once. When this approach is implemented, selecting
the right jS's, the slack on the control constraints takes some care. When a diagnosis
is common, we can be more stringent than when the diagnosis is rare. Similarly, our
Rofecoxib
Members
47
27
26
31
36
21
42
44
52
44
45
40
34
33
36
83
69
53
109
114
114
116
156
116
171
Naproxen
Members
41
28
22
22
23
27
24
31
35
36
36
32
29
42
38
41
40
39
58
45
53
57
99
86
78
results suggest that including very sick members (in the pre-treatment period) who
have a lot of diagnoses constrains the optimal solution of the optimization problem.
Removing the pre-treatment "top spenders" improves the optimal solution (the sam-
ple size). Our optimization method produced results similar to those from simpler
selection methods and we therefore omit them.
3.7.4 Results from Methods with a Baseline Rate
The study period is from July 2000 (the date of the first rofecoxib prescription in
our data set) through March 2005 (6 months after rofecoxib was withdrawn from
the market). Our experiment tests across all 328 coding groups. We compare the
results from finding a baseline by adjusting the comparison population by age, gender
and cost bucket to the results from following the relative changes in coding in both
populations independently. We furthermore investigate different requirements for the
minimum number of days taking the drugs and different definitions of events.
We analyze the time until the known side effects; cardiac events and stroke are flagged
through the drug surveillance. We also pay special attention to renal coding since a
meta-study from 2006 [62] found an increase in renal risk as a result of taking rofe-
coxib.
We first analyze the results of adjusting the comparison population for age and
gender. The results are functions of both how we limit our population (minimum
number of days taking the drug) and how we define an event (claims-line, claims-day,
claims-event). Moreover, whether we raise an alarm is a function of how we set our
confidence intervals. Finally, to avoid false positives due to unstable risk estimators,
we set a minimum number of observed events in the post-treatment period that need
to be observed, before an flag can be raised.
Table 3.9 compares the results for different minimum days and definitions of events
Settings (MinDays, Cardiac Stroke Renal Fail- Secondary Number
Event) ure Renal of False
Coding Positives
(0,line) - 43 47 - 121
(0,event(30)) - 54 - - 88
(0,event(1500)) - 51 - - 73
(30,line) - 41 36 - 188
(30,event(30)) - 55 - - 26
(30,event (1500)) 53 40 36 - 176
Table 3.9: The result of running age- and gender-adjusted population selection. If a
known side effect was detected, the number represents the month of detection. The
primary and secondary upper bounds were set to 97.5% and 95% respectively, and
we required a minimum of 20 observed events in the post-treatment-period.
for the age-gender adjusted methodology. We note that we succeed in detecting stroke
across different settings, but the same cannot be said for the cardiac events, which
we detect only once. These succesful detections are outweighed by a very high false
alarm rate, which makes this approach unsuccessful. It is therefore clear that ad-
justing only for age and gender does too little to adjust for prior differences between
the two populations. Figure 3-2 shows how the numbers of cardiac events, stroke,
and renal failure evolve over time compared to the confidence interval around the
expected number of events. In the same figure we display the event data for the di-
agnosis of thyroid problems, which was signaled as a side effect, but is a false positive.
A member's health care cost is a good proxy for his or her overall health condition.
We therefore split our population into cost buckets similar to those introduced in
Section 2.2.3, adjusted for increases in health care cost, (as this is an older dataset).
We adjust our estimates based on cost buckets and gender (we exclude age-groups
in the adjustment as it would segment the data into too many subgroups, resulting
in unstable baseline estimates). Table 3.10 shows the results for the same parameter
settings as before for the age-gender adjusted methodology in Table 3.9. We note
that we still have too many false positives, but all settings correctly identify stroke
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Figure 3-2: The number of observed events compared to a 95% confidence intervals
constructed from the naproxen population estimates, for 4 conditions: 3 known side
effects as well as thyroid problems. The x-axis is the number of months from the
start of the study.
and renal failure as a side effects, and they do so faster than the age-gender adjusted
method. The number of false positives is similar or higher. The two adjustment
methods therefore performed similarly.
3.7.5 Results from Methods without Baseline Rate
We now look at the results from running the drug surveillance without a predefined
baseline. In order to raise an alarm, the estimate of the relative risk needs to have
stabilized. As we see from Figure 3-3, this stabilization does not occur until around
week 50 for many of the conditions. One of the main reasons is that for the first 3
years of the study, there are very few members in the data, and it is not until 2004
Stroke
Renal Failure Thyroid 
Conditions
nnn
Settings (MinDays, Cardiac Stroke Renal Fail- Secondary Number
Event) ure Renal of False
Coding Positives
(0,linect ) - 35 37 - 142
(0,event (30)) - 36 40 - 121
(0,event(1500)) 46 36 41 - 109
(30,linect ) 56 28 32 - 179
(30,event(30)) - 40 31 - 40
(30,event (1500)) - 31 40 - 171
Table 3.10: The result of running cost bucket- and gender-adjusted population se-
lection. If a known side effect was detected, the number represents the month of
detection. The primary and secondary upper bounds were set to 97.5% and 95%
respectively, and we required a minimum of 20 observed events in the post-treatment-
period.
that we have a significant number of members taking rofecoxib. We therefore first
test for stability of our estimates, and only if a condition passes the stability test
do we analyze if the relative risk is significantly larger for the rofecoxib members
than for the naproxen members. If a condition raises an alarm, it enters a six-month
false-positive-period, designed to catch false positives due to temporary stabilization
of the estimates.
Analyzing the Whole Population
Running the analysis resulted in 21 flags being raised, two of which are cardiac events
and stroke. From Table 3.11 we note that at the time of alarm, we estimate the rela-
tive risk of strokes to be 4.38 and those of heart attack to be 4.04. We did not detect
increased risk of renal failure. Out of the 19 other alarms, 8 of the conditions are
related to the circulatory system and might therefore be related to a wider cardiac
effect of rofecoxib than previously acknowledged.
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Figure 3-3: The estimates for the relative risk for four conditions over time. The
horizontal line is the estimated relative change for naproxen.
Condition Time at Detection Relative Risk at Detection
Cardiac Events 55 (29) 4.002
Stroke 41 (15) 4.384
Renal Failure Not detected
Table 3.11: Relative risk for known side effects at the time of detection. The number
in parentheses is the number of months since September 2002.
Analyzing the Population by Cost Bucket
Table 3.12 shows the estimated risk for the known side-effects and thyroid problems,
by cost buckets. We observe that the expected elevated risks of the known side ef-
fects are visible in the lower buckets, but they disappear in upper buckets. Sick
members have a lot of pre-treatment coding, resulting in increased variability in the
estimates. This observation motivates a further study into how the lower cost buckets
(the healthier population) can be used for drug surveillance, rather than the popu-
Cardiac Events Stroke
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lation as a whole. Figure 3-4 shows the estimates of the relative risk, for bucket 1
members for cardiac events, stroke, renal failure and thyroid problems as a function
of time. We note that the estimates again do not stabilize until around week 50.
Minimum Cost Cardiac Renal Thyroid
Days on Drug Bucket Events Failure Stroke Problems
1 1.487 1.381 2.138 -0.110
2 0.022 4.434 0.179 -0.407
0 3 -0.006 0.129 -0.215 -0.456
4 -0.844 -0.533 -0.524 -0.434
5 -0.324 -0.831 -0.493 -0.480
1 2.829 5.982 2.592 -0.113
2 0.181 3.724 0.229 -0.412
30 3 -0.193 0.110 -0.242 -0.485
4 -0.910 -0.369 -0.519 -0.492
5 0.008 -0.856 -0.535 -0.395
Table 3.12: Relative risk for known side effects and thyroid problems. For example,
we observe an almost six-fold risk in renal failure for bucket 1 members (this in large
part due to very few events in the pre-treatment history) if we require members to
have been prescribed a minimum of 30 days of rofecoxib.
Running the drug surveillance using bucket 1 members only results in a reduced num-
ber of flags being raised significantly. Table 3.13 summarizes the information about
the flags raised. Seven conditions were flagged, including stroke and cardiac events,
the known side effects of rofecoxib. Two other conditions related to the circulatory
system were flagged, raising questions about wider cardiac effects of rofecoxib (as we
saw previously when we ran the analysis on all buckets). Another condition that was
flagged is hypertensive chronic kidney disease, a sign of deteriorating kidney health,
which is connected to the known effects of rofecoxib on the kidneys. Two other condi-
tions get flagged, one of which, "other conditions originating in the perinatal period,"
we catch as a false positive in the six-month-long follow-up period, leaving "congen-
ital anomalies of urinary system" as a false positive. This condition has very few
events in both the pre-treatment and post-treatment periods with a pre-treatment
1UU
80
60
40
20
0n
OU
40
20
n
Cada Eet SrkIOU
100
50
0
-50A
0 20 40 60 0 20 40 60
Renal Failure Thyroid Conditions
3U
20
10
0
_110
30 40 50 60 0 20 40 60
Figure 3-4: The figure shows, for bucket 1 members, how the estimate for the relative
risk for rofecoxib members changes, for four different conditions: Cardiac events,
stroke, renal failure and thyroid problems. The horizontal line in each subfigure is
the relative change for the naproxen population.
p=0.0000391. Furthermore the corresponding relative risk for naproxen members is
1.96, indicating that there might be a systematic increase in relative risk and that our
estimate has not gone down enough when the study ends (due to very few observed
events). Using only the bucket one population reduces the number of false positives,
while detecting both cardiac events and stroke.
Renal Failure
As previously discussed, renal failure became a known side effect of rofecoxib after
the drug was withdrawn. When running the analysis on bucket 1 only, we did not
flag renal failure (however, we did observe kidney disease). When the surveillance is
StrokeCardiac Events
i
Condition Time Relative Relative Change
until Risk at Risk at between
Dis- t min(t + t and
covery 6, 57) t + 6
(t)
Cardiac Events 55(29) 2.74 2.83 3.12%
Stroke 51 (23) 2.72 2.59 -4.8%
Hypertensive chronic kidney disease 45 (19) 10.3 12.0 16.5%
Angina pectoris , excluding 413.0 56 (30) 2.24 2.24 0%
Portal vein thrombosis, venous em- 52 (26) 2.41 2.54 5%
bolism and throbosis
Congenital anomalies of urinary sys- 52 (26) 3.80 3.73 -2%
tem
Other conditions originating in the 49 (23) 2.13 1.92 -10%
perinatal period
Table 3.13: The side effects identified by the relative risk methodology, using popula-
tion from bucket 1 only. The numbers in parenthesis are the number of months from
September 2002.
run on buckets 2 through 5, only one condition is flagged, renal failure in bucket 2.
One of the reasons we see renal failure in bucket 2 and not in bucket 1 is that healthy
kidneys do not go into renal failure right away (unlike a heart attack which may have
no prior indications and therefore no prior costs). Kidneys progressively get worse
until they reach the stage of renal failure. Due to the biologics of rofecoxib, healthy
kidneys (as are most kidneys in members in bucket 1) are not affected by rofecoxib as
much as troubled kidneys, such as those that might be found in members in the upper
buckets. Table 3.14 shows the time, relative risk and change during the six-month
false-positive control period for the renal failure condition in bucket 2.
This observation raises the point that looking at bucket 1 may not be enough when
looking for adverse events that cannot (or rarely) originate from bucket 1. Those
events are few, and we leave it to implementation with medical expertise to define
the appropriate surveillance buckets for those events.
Condition Time Relative Relative Change
until Risk at Risk at between
Dis- t t + 6 t and
covery t + 6
(t)
Acute renal failure and unspecified re- 51 (25) 3.59 3.94 10%
nal failure
Table 3.14: The side effects identified by the relative risk methodology, using popu-
lation from buckets 2 through 5. The number in parenthesis is the number of months
from September 2002.
3.7.6 Conclusions
In this section we have shown that we can effectively way follow the changes in rel-
ative risk and discover false positives sooner than with the current post surveillance
system. We have also shown that the key to a successful system, is to follow bucket
one members only, except for few conditions that cannot arise among bucket one
members. This approach reduces the variance in the system and leads to more stable
estimates and many fewer false positives. We have also found that the most appropri-
ate definition of events is to count only first occurrences of conditions (claims-period
events, with large d), rather than define events as claims-lines or claim-day, as this
approach also reduces the variability in the system.
From our analysis, we have learned that it takes between 2 and 3 years, after we
get a significant amount of data, to detect cardiac events, stroke and kidney prob-
lems. It is therefore clear that many adverse events could have been prevented if
active real-time drug surveillance had been in place during the rofecoxib years.
3.8 Case Study: Atorvastatin vs. Simvastatin
Atorvastatin, marketed under the name Lipitor, is now one of the largest selling drugs
in the world, with US sales in 2006 exceeding $12.9 billion. Marketed by Pfizer, the
drug belongs to the class of pharmaceuticals called statins. It is used to control
elevated cholesterol levels and, as a result, lowers the risk of cardiovascular disease.
Another statin is simvastatin, better known under the marketing name Zocor, which
in medical studies has been shown to have efficacy and toxicity profile similar to
atorvastatin [35, 66].
3.8.1 The Data
In our dataset we have over 57,000 members who have taken atorvastatin (thereof
over 56,000 in bucket 1) and close to 23,000 members (close to 22,000 in bucket 1)
who have taken simvastatin. Table 3.15 summarizes some of the key parameters for
the statin members. For example, we note that average age is 55 and 56 years for
atorvastatin and simavastatin respectively. The study period was from September
1999 through August 2005.
Drug Cost Count Avg. Avg. Avg. Avg. Avg.
Bucket Age Days Pre- Post- Monthly
on treatment treatment Pre-
Drug Months Months treatment
Costs
Atorvastatin 1 56,035 55 1196 10 28 229
Simvastatin 1 21,935 56 832 11 31 266
Atorvastatin all 57,578 55 1203 10 28 567
Simvastatin all 22,812 56 868 11 31 891
Table 3.15: Data summary for atorvastatin (Lipitor) and simvastatin (Zocor).
3.8.2 Results
We applied the same methodology and parameter settings as with rofecoxib and
naproxen. Table 3.16 shows the flags that were raised, and the changes in the six-
month follow-up period. We note that all the flags raised get caught as false positives
in the follow-up period.
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Table 3.16: The side effects identified by the relative risk methodology,
lation from bucket 1 only and the settings from the rofecoxib study.
using popu-
Looking at the estimates for the relative risk, we notice less variance than with the
estimates using the rofecoxib data. One reason is that the average post-treatment
period is longer and the population is taking the drug for longer periods. We there-
fore adjust the parameters accordingly and rerun the analysis. As a result of the new
parameter settings, one flag was raised, for other psychoses. As Figure 3-5 shows, a
flag is raised when the relative risk is stable for a couple of months, 4 years into the
study. The risk goes down in the following months, and therefore the condition is
labeled as a false positive in the six-month follow-up period.
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Drug Condition Time Relative Relative Change
until risk at risk at in 6
Discovery t min(t+ months
(t) 6,57)
Zocor Malignant neoplasm of bone, 45 6.59 3.99 -39.5%
connective tissue, skin, and
breast
Lipitor Symptoms involving nervous 48 4.27 1.71 -60.0%
and musculoskeletal systems
Zocor Other psychoses 48 13.62 6.26 -54.1%
Lipitor Cataract 49 3.08 1.80 -41.5%
Lipitor Disorders of the autonomic ner- 50 3.74 1.96 -47.5%
vous system
Lipitor Other disorders of soft tissues 51 2.52 1.04 -58.9%
Zocor Hyperkinetic syndrome 52 7.80 3.17 -59.4%
Zocor Varicose veins of lower extremi- 52 2.99 2.28 -23.8%
ties and other sites
Zocor Fitting and adjustment of pros- 60 3.50 1.99 -43.0%
thetic device, implant or other
device
Zocor Disorders resulting from im- 68 2.40 2.02 -15.9%
paired renal function
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Figure 3-5: The estimate of the relative risk for "other psychoses" during the study
period. The x-axis represents the number of months from September 2000.
3.8.3 Conclusions
The results from this study indicate that atorvastatin and simvastatin have similar
side effects, as suggested in the medical literature. Furthermore, the study indicates
that the methodology developed in previous sections can work across different drugs.
An interesting future study would be to compare simvastatin and atorvastatin to a
sample from the general population, to better understand the drugs' toxicity profiles.
3.9 Case Study: Sildenafil vs. Tadalafil
Sildenafil, known under the marketing names Viagra, Revatio and others, is a drug
used to treat male erectile dysfunction (impotence) and pulmonary arterial hyper-
tension. Viagra was launched in 1998 and had the fastest initial sales growth of any
pharmaceutical product following its launch [39]. In 2000, it had 92 percent of the
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global market for prescribed erectile dysfunction pills. One of Viagra's main competi-
tors today is tadalafil, better known under the marketing name of Cialis. Tadalafil was
approved by the FDA in November 2003. One advantage tadalafil has over sildenafil
(and vardenafil, known under the marketing name Levitra) is its 17.5 hour half-life,
compared to 4 hours for sildenafil, earning Cialis the nickname "the weekend pill."
Sildenafil has some rare but serious side effects, including the following: priapism,
severe hypotension, myocardial infarction, ventricular arrhythmias, stroke and in-
creased intraocular pressure, especially in men with heart conditions. More common,
but less serious side effects include diarrhea, dizziness, dyspepsia, facial flushing,
headache, nasal congestion, rash, sneezing, palpitations, photophobia, upset stomach
and urinary tract infection [6, 49, 32]. These side effects reflect the ability of silde-
nafil to cause blood vessels to widen. Tadalafil has many side effects in common with
sildenafil [26], as both drugs belong to the same drug class and therefore work in
similar ways. The most common side effects of tadalafil are headache, indigestion,
back pain, muscle aches, flushing, and stuffy or runny nose.
In May of 2005, the U.S. Food and Drug Administration issued a warning that silde-
nafil (as well as tadalafil and vardenafil) could lead to vision impairment [30], and
in October 2007, the FDA required labeling for sildenafil (and other similar drugs
including tadalafil) to warn users of the potential risk of sudden hearing loss [31].
In this case study, we apply the relative risk methodology and compare sildenafil
to tadalafil. As the drugs share many side effects, the goal is to evaluate if there is a
difference between the two drugs, as opposed to flagging all side effects. An interest-
ing study would be to compare those men taking sildenafil to the general population,
but that is outside the scope of this chapter.
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3.9.1 The Data
The study uses the same database as in the previous two case studies. The data in-
cludes 11,401 sildenafil members and 1,931 tadalafil members after excluding women
(277 members) and members under 20 (46 additional members). Most of the mem-
bers are in bucket one, as Table 3.17 shows. The first prescription for tadalafil is in
December 2003, and the last is in October 2005. Due to the late introduction of Cialis
to our dataset, the average number of months after starting treatment is much lower
for tadalafil than for sildenafil. To overcome this difference ( longer post-treatment
period allows for a longer time for events to happen), we adjust the post-treatment
histories for the sildenafil members. For same reasons, the pre-treatment period is
longer for the tadafil members and we adjust the pre-treatment data in the same way.
We furthermore compare the surveillance results using adjusted histories with the
outcome when we do not adjust the length of pre- and post-histories. We note that in
other ways the populations are quite similar: the average age of the two populations
is almost the same (52 and 53 years) and the average pre-treatment monthly cost is
close ($223 and $290 for bucket one members).
Drug Cost Count Avg. Avg. Avg. Avg. Avg.
Bucket Age Days Pre- Post- Monthly
on treatment treatment Pre-
Drug Months Months treatment
Costs
Tadalafil 1 1,882 52 80 18 12 290
Sildenafil 1 11,158 53 126 11 23 223
Tadalafil all 1,931 52 81 18 12 475
Sildenafil all 11,401 53 128 11 23 406
Table 3.17: Data summary for sildenafil (Viagra) and tadalafil (Cialis).
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3.9.2 Results
Tadalafil has a short timeframe in our datasets, and a small sample size. We therefore
do not expect to be able to detect many differences as not all estimators of adverse
events will have stabilized in 2 years with only 2,000 members. We ran the experiment
both with and without requirements for the minimum number of days that the mem-
bers took the drugs, and with and without adjustments to pre- and post-treatment
histories. Table 3.18 shows the flags raised as a result of our analysis. No flags were
raised when the analysis was run with no requirement on minimum number of days
on the drugs (both with and without adjusting the histories). When we required 30
days as the minimum number of days taking the drugs, one flag was raised (both
with and without history adjustment), but it had very few events behind it in the
post-treatment period (nine events), and was caught by the six-months false-positive
surveillance period. Figure 3-6 shows the relative risk estimate during the study pe-
riod; we note that it temporarily levels off around month 15 but then continues to fall.
Min History Condition Sildenafil Tadalafil Month
Days Ad- Rel. Rel.
on just- Risk Change
Drug ment
30 No Special screening for -30.5% 235.3% 17
endocrine, nutritional,
metabolic, and immunity
disorders
30 Yes Special screening for -30.7% 235.3% 17
endocrine, nutritional,
metabolic, and immunity
disorders
Table 3.18: Flags raised for sildenafil (Viagra) and tadalafil(Cialis). No flags were
raised for when no requirement was put on the minimum numbers of days a member
needed to take the drug in order to be included in the analysis. Month refers to the
number of months after the first tadalafil prescription.
In conclusion, due to limitations in our data (very few events) we are unable to detect
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Figure 3-6: The estimate of the relative risk for "special screening for endocrine,
nutritional, metabolic, and immunity disorders". The x-axis represents the number
of months from the start of the study (December 2003).
any differences in side effects between tadalafil and sildenafil, if there are any. The
condition that was flagged had less than ten observed events in the post-treatment
period and was labeled as a false positive in the six-month follow-up period. This
finding indicates that our methodology does not raise unwanted alarms when dealing
with smaller populations.
3.10 Conclusions
In this chapter we have laid the foundations for a surveillance system for drugs in
common use. We ran three case studies that show promising results and encourage
further study.
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The rofecoxib case study highlighted some of the difficulties with setting up a ro-
bust system. We found that it is not enough to select similar drugs: prior differences
need to be accounted for. We introduced pre-treatment and post-treatment relative
change as the measure to achieve that goal. We also introduced several mathematical
programming formulations of the population selection problem and believe, although
they did not prove to be completely successful in our case study (in part due to a
small sample size) that they have potential to aid in population selection when drug
surveillance is run against a comparative baseline.
The two other case studies showed that the methodology developed did not raise
any unexpected flags or have a high rate of false positives (none in our two studies)
when applied to broader range of drugs classes.
This study shows that drug surveillance using claims data could become one of FDA's
standard tools for post-marketing surveillance. The methodology introduced here
should be further developed on drugs with known side effects, which will highlight
more challenges and be a valuable learning process. Some of the refinements that
will further fine-tune the methods are a) to use medical knowledge to create a better
grouping of ICD-9 codes; b) to implement definitions of events as functions of the
underlying conditions, with acute events treated differently than chronic conditions;
and c) to analyze the optimal setting of the upper confidence intervals, to strike a
balance between the expected time until discovery of a true side effect and the prob-
ability of a false positive.
In conclusion, in this chapter we have emphasized finding side effects. With the
same methodology we can potentially find unexpected benefits of drugs currently on
the market.
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3.A Appendix - Grouping of Codes Used in Case
Studies
Table 3.19 shows the ICD-9 groupings used in the study. The group descriptions are
based on [4].
Table 3.19
Description
Intestinal infectious diseases
Tuberculosis
Zoonotic bacterial diseases
Other bacterial diseases
Human immunodeficiency virus infection
Poliomyelitis and other non-arthropod-borne viral diseases of
central nervous system
Viral diseases accompanied by exanthem
Other human herpesviruses
Arthropod, borne viral diseases
Other diseases due to viruses and chlamydiae
Rickettsioses and other arthropod-borne diseases
Syphilis and other venereal diseases
Other spirochetal diseases
Mycoses
Helminthiases
Other infectious and parasitic diseases
Late effects of infectious and parasitic diseases
Malignant neoplasm of lip, oral cavity, and pharynx
Malignant neoplasm of digestive organs and peritoneum
Malignant neoplasm of respiratory and intrathoracic organs
Malignant neoplasm of bone, connective tissue, skin, and breast
ICD-9 Code
001.x - 009.x
010.x - 018.x
020.x - 027.x
030.x - 041.x
042.x
045.x - 049.x
050.x - 057.x
058.x
060.x - 066.x
070.x - 079.x
080.x - 088.x
090.x - 099.x
100.x - 104.x
110.x - 118.x
120.x - 129.x
130.x - 136.x
137.x - 139.x
140.x - 149.x
150.x - 159.x
160.x - 165.x
170.x - 176.x
Continued on next page...
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Table 3.19 - Continued
Description
Malignant neoplasm of genitourinary organs
Malignant neoplasm of other and unspecified sites
Malignant neoplasm of lymphatic and hematopoietic tissue
Benign neoplasms
Carcinoma in situ
Neoplasm of uncertain behavior
Neoplasm of unspecified nature
Disorders of thyroid gland
Diseases of other endocrine glands
Nutritional deficiencies
Other metabolic and immunity disorders
Anemias
Diseases of white blood cells
Other diseases of blood and blood-forming organs
Dementias
Alcohol and drug induced mental disorders
Drug-induced mental disorders
Transient mental disorders due to conditions classified elsewhere
Persistent mental disorders due to conditions classified elsewhere
Schizophrenic disorders
Episodic mood disorders
Other psychoses
Pervasive developmental disorders
Anxiety, reactions to stress or adjustment reaction
Personality disorders
Sexual and gender identity disorders
ICD-9 Code
179.x - 189.x
190.x - 199.x
200.x - 208.x
210.x - 229.x
230.x - 234.x
235.x - 238.x
239.x
240.x - 246.x
250.x - 259.x
260.x - 269.x
270.x - 279.x
280.x - 287.x
288.x
289.x
290.x
291.x
292.x
293.x
294.x
295.x
296.x
298.x
299.x
300.x, 308.x,
309.x
301.x
302.x
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Table 3.19 - Continued
Description
Alcohol dependence, drug dependence or nondependent abuse
of drugs
Physiological malfunction arising from mental factors, special
symptoms or syndromes
Specific nonpsychotic mental disorders due to brain damage
Depressive disorder, not elsewhere classified
Disturbance of conduct, not elsewhere classified
Disturbance of emotions specific to childhood and adolescence
Hyperkinetic syndrome of childhood
Specific delays in development
Psychic factors associated with diseases classified elsewhere
Mental retardation
Meningitis
Encephalitis, myelitis, and encephalomyelitis
Intracranial and intraspinal abscess
Phlebitis and thrombophlebitis of intracranial venous sinuses
Late effects of intracranial abscess or pyogenic infection
Organic sleep disorders
Cerebral degenerations
Parkinson's disease
Other extrapyramidal disease and abnormal movement disorders
Spinocerebellar disease
Anterior horn cell disease
Other diseases of spinal cord
Disorders of the autonomic nervous system
Pain, unspecified by location
ICD-9 Code
303.x, 31
305.x
306.x, 307.x
310.x
311.x
312.x
313.x
314.x
315.x
316.x
317.x - 319.x
320.x, 3
322.x
323.x
324.x
325.x
326.x
327.x
330.x, 331.x
332.x
333.x
334.x
335.x
336.x
337.x
338.x
34.x,
21.x,
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Table 3.19 - Continued
Description
Multiple sclerosis
Other demyelinating diseases of central nervous system
Hemiplegia and hemiparesis
Other paralytic syndromes
Epilepsy and recurrent seizures
Migraine
Cataplexy and narcolepsy
Other conditions of brain
Other and unspecified disorders of the nervous system
Trigeminal nerve disorders
Facial nerve disorders
Disorders of other cranial nerves
Nerve root and plexus disorders
Mononeuritis of upper limb, lower lip and mononeuritis multi-
plex
Hereditary and idiopathic peripheral neuropathy
Inflammatory and toxic neuropathy
Myoneural disorders
Muscular dystrophies and other myopathies
Disorders of the globe, retinal (exluding 361.x) iris, ciliary body,
refraction, accommodation, conjunctiva, lacrimal, cornia orbit,
optic nerve and visual pathways.
Retinal detachments and defects
Chorioretinal inflammations, scars, and other disorders of
choroid
ICD-9 Code
340.x
341.x
342.x
344.x
345.x
346.x
347.x
348.x
349.x
350.x
351.x
352.x
353.x
354.x, 355.x
356.x
357.x
358.x
359.x
360.x,
364.x,
371.x,
375.x,
377.x,
361.x
363.x
362.x,
367.x,
372.x,
376.x,
379.x
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Table 3.19 - Continued
Description
Glaucoma
Cataract
Visual disturbances
Blindness and low vision
Keratitis
Inflammation of eyelids and other disorders of eyelids
Strabismus and other disorders of binocular eye movements
Disorders of external ear
Nonsuppurative otitis media and eustachian tube disorders
Suppurative and unspecified otitis media
Mastoiditis and related conditions
Vertiginous syndromes and other disorders of vestibular system
Otosclerosis
Other disorders of ear(including tympanic membrane, middle
ear and mastroid
Hearing loss
Acute rheumatic fever
Chronic rheumatic heart disease
Essential or secondary hypertension
Hypertensive heart disease
Hypertensive chronic kidney disease
Hypertensive heart and chronic kidney disease
Acute myocardial infarction, and other acute and subacute
forms of ischemic heart disease
Old myocardial infarction
Angina pectoris , excluding 413.0
Other forms of chronic ischemic heart disease
ICD-9 Code
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365.x
366.x
368.x
369.x
370.x
373.x, 374.x
378.x
380.x
381.x
382.x
383.x
386.x
387.x
388.x, 385.x
386.x
389.x
390.x - 392.x
393.x - 398.x
401.x, 405.x
402.x
403.x
404.x
410.x, 411.x
412.x
413.x
414.x
Table 3.19 - Continued
Description
Diseases of pulmonary circulation
Other forms of heart disease
Cerebrovascular disease
Diseases of arteries, arterioles, and capillaries
Phlebitis and thrombophlebitis
Portal vein thrombosis, venous embolism and throbosis
Varicose veins of lower extremities and other sites
Hemorrhoids
Noninfectious disorders of lymphatic channels
Hypotension
Other disorders of circulatory system
Acute respiratory infections
Other diseases of the upper respiratory tract
Pneumonia and influenza
Chronic obstructive pulmonary disease and allied conditions
Pneumoconioses and other lung diseases due to external agents
Other diseases of respiratory system
Disorders of tooth development and eruption
Diseases of hard tissues of teeth ,
Diseases of pulp and periapical tissues
Gingival and periodontal diseases
Dentofacial anomalies, including malocclusion
Other diseases and conditions of the teeth and supporting struc-
tures
Diseases of the jaws
Diseases of the salivary glands
ICD-9 Code
415.x - 417.x
420.x - 429.x
430.x - 438.x
440.x - 449.x
451.x.
452.x, 453.x
454.x, 456.x
455.x
457.x
458.x
459.x
460.x - 466.x
470.x - 478.x
480.x - 488.x
490.x - 496.x
500.x - 508.x
510.x - 519.x
520.x
521.x
522.x
523.x
524.x
525.x
526.x
527.x
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Table 3.19 - Continued
Description
Diseases of the oral soft tissues, excluding lesions specific for
gingiva and tongue
Diseases and other conditions of the tongue
Diseases of esophagus
Gastritis and duodenitis
Gastric, duodenal, petic, gastrojejunal ulcers and gastric mu-
cositis
Disoiders of function of stomach, and other disorders of stomach
and duodenum
Appendicitis
Hernia of abdominal cavity
Noninfectious enteritis and colitis
Condition of the liver
Cholelithiasis and other disorders of gallbladder and biliary tract
Diseases of pancreas
Gastrointestinal hemorrhage
Intestinal malabsorption
Acute glomerulonephritis, nephrotic syndrome, chronic
glomerulonephritis, nephritis and nephropathy, not specified as
acute or chronic
Acute renal failure and unspecified renal failure
Chronic kidney disease (ckd)
Renal sclerosis, unspecified
Disorders resulting from impaired renal function
Small kidney of unknown cause
Infections of kidney
Hydronephrosis
ICD-9 Code
528.x
529.x
530.x
535.x
531.x - 534.x,
538.x
536.x, 537.x
540.x
550.x
555.x
570.x
574.x
577.x
578.x
579.x
580.x
- 543.x
- 553.x
- 558.x
- 573.x
- 576.x
- 583.x
584.x, 586.x
585.x
587.x
588.x
589.x
590.x
591.x
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Table 3.19 - Continued
Description
Calculus of kidney, ureter or lower urinary tract
Other disorders of kidney and ureter
Cystitis and other disorders of bladder
Urethritis, not sexually transmitted, and urethral syndrome,
urethral stricture and other disorders of urethra and urinary
tract
Hyperplasia of prostate
Inflammatory diseases of prostate
Other disorders of prostate
Hydrocele
Orchitis and epididymitis
Redundant prepuce and phimosis
Infertility, male
Disorders of penis
Other disorders of male genital organs
Benign mammary dysplasias
Other disorders of breast
Inflammatory disease of female pelvic organs
Endometriosis
Genital prolapse
Fistula involving female genital tract
Noninflammatory disorders of ovary, fallopian tube, broad liga-
ment, cervix, vagina, vulva or perineum
Disorders of uterus, not elsewhere classified
Pain and other symptoms associated with female genital organs
Disorders of menstruation and other abnormal bleeding from
female genital tract
ICD-9 Code
592.x, 594.x
593.x
595.x, 596.x
597.x - 599.x
600.x
601.x
602.x
603.x
604.x
605.x
606.x
607.x
608.x
610.x
611.x
614.x
617.x
618.x
619.x
620.x,
624.x
621.x
625.x
626.x
- 616.x
622.x -
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Table 3.19 - Continued
Description
Menopausal and postmenopausal disorders
Infertility, female
Other disorders of female genital organs
Ectopic and molar pregnancy
Other pregnancy with abortive outcome
Complications mainly related to pregnancy
Normal delivery, and other indications for care in pregnancy,
labor, and delivery
Complications occurring mainly in the course of labor and de-
livery
Complications of the puerperium
Carbuncle and furuncle
Cellulitis and abscess
Acute lymphadenitis
Impetigo
Pilonidal cyst
Other local infections of skin and subcutaneous tissue
Erythematosquamous dermatosis
Atopic dermatitis and related conditions, contact dermatitis and
other eczema
Dermatitis due to substances taken internally
Bullous dermatoses
Erythematous conditions
Psoriasis and similar disorders
Lichen
Pruritus and related conditions
Corns and callosities
ICD-9 Code
627.x
628.x
629.x
630.x
634.x
640.x
650.x
633.x
639.x
649.x
659.x
660.x - 669.x
670.x - 677.x
680.x
681.x, 682.x
683.x
684.x
685.x
686.x
690.x
691.x ,692.x
693.x
694.x
695.x
696.x
697.x
698.x
700.x
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Table 3.19 - Continued
Description
Other hypertrophic and atrophic conditions of skin
Other dermatoses
Diseases of nail
Diseases of hair and hair follicles
Disorders of sweat glands
Diseases of sebaceous glands
Chronic ulcer of skin
Urticaria
Other disorders of skin and subcutaneous tissue
Diffuse diseases of connective tissue
Arthropathy associated with infections
Crystal arthropathies
Arthropathy associated with other disorders classified elsewhere
Rheumatoid arthritis and other inflammatory polyarthropathies
Osteoarthrosis and allied disorders
Other and unspecified arthropathies
Internal derangement and other unsprecified disorders of joins
(includes knees)
Ankylosing spondylitis and other inflammatory spondylopathies
Spondylosis and allied disorders
Intervertebral disc disorders
Other disorders of cervical region and back
Polymyalgia rheumatica
Peripheral enthesopathies and allied syndromes
Other disorders of synovium, tendon, and bursa
Disorders of muscle, ligament, and fascia
Other disorders of soft tissues
ICD-9 Code
701.x
702.x
703.x
704.x
705.x
706.x
707.x
708.x
709.x
710.x
711.x
712.x
713.x
714.x
715.x
716.x
717.x, 718.x,
719.x
720.x
721.x
722.x
723.x, 724.x
725.x
726.x
727.x
728.x
729.x
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Table 3.19 - Continued
Description
Osteomyelitis, periostitis, and other infections involving bone
Osteitis deformans and osteopathies associated with other dis-
orders classified elsewhere
Osteochondropathies
Other disorders of bone and cartilage
Flat foot
Acquired deformities of limbs (excluding curvature of spine)
Curvature of spine
Nonallopathic lesions, not elsewhere classified
Anencephalus and similar anomalies
Spina bifida
Other congenital anomalies of nervous system
Congenital anomalies of eye, ear, face, and neck
Bulbus cordis anomalies and anomalies of cardiac septal closure
Other congenital anomalies of heart and the circulatory system
Congenital anomalies of respiratory system
Cleft palate and cleft lip
Other congenital anomalies of upper alimentary tract and diges-
tive system
Congenital anomalies of genital organs
Congenital anomalies of urinary system
Certain congenital musculoskeletal deformities
Other congenital anomalies of limbs and musculoskeletal anoma-
lies
Congenital anomalies of the integument
Chromosomal anomalies
ICD-9 Code
730.x
731.x
732.x
733.x
734.x
735.x, 736.x,
738.x
737.x
739.x
740.x
741.x
742.x
743.x, 744.x
745.x
746.x, 747.x
748.x
749.x
750.x
752.x
753.x
754.x
755.x, 756.x
757.x
758.x
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Table 3.19 - Continued
Description
Other and unspecified congenital anomalies
Maternal causes of perinatal morbidity and mortality
Other conditions originating in the perinatal period
General symptoms
Symptoms involving nervous and musculoskeletal systems
Symptoms involving skin and other integumentary tissue
Symptoms concerning nutrition, metabolism, and development
Symptoms involving head and neck
Symptoms involving cardiovascular system
Symptoms involving respiratory system and other chest symp-
toms
Symptoms involving digestive system
Symptoms involving urinary system
Other symptoms involving abdomen and pelvis
Nonspecific findings on examination of blood
Nonspecific findings on examination of urine
Nonspecific abnormal findings in other body substances
Nonspecific abnormal findings on radiological and other exami-
nation of body structure
Nonspecific abnormal results of function studies
Other and nonspecific abnormal cytological, histological, im-
munological and dna test findings
Other nonspecific abnormal findings
Ill-defined and unknown causes of morbidity and mortality
Persons with potential health hazards related to communicable
diseases
ICD-9 Code
759.x
760.x - 763.x
764.x - 779.x
780.x
781.x
782.x
783.x
784.x
785.x
786.x
787.x
788.x
789.x
790.x
791.x
792.x
793.x
794.x
795.x
796.x
797.x - 799.x
v01.x - v06.x
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Table 3.19 - Continued
Description
Persons with need for isolation, other potential health hazards
and prophylactic measures
Persons with potential health hazards related to personal and
family history
Persons encountering health services in circumstances related to
reproduction and development
Liveborn infants according to type of birth
Persons with a condition influencing their health status
Elective surgery for purposes other than remedying health states
Aftercare involving the use of plastic surgery
Fitting and adjustment of prosthetic device, implant or other
device
Other orthopedic aftercare
Attention to artificial openings
Encounter for dialysis and dialysis catheter care
Care involving use of rehabilitation procedures
Encounter for other and unspecified procedures and aftercare
Donors
Persons encountering health services in other circumstances
General medical examination
Observation and evaluation for suspected conditions not found
Special investigations and examinations
Special screening examination for viral and chlamydial diseases
Special screening examination for bacterial and spirochetal dis-
eases
Special screening examination for other infectious diseases
Special screening for malignant neoplasms
ICD-9 Code
Continued on next page...
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v07.x - v09.x
vl0.x - v19.x
v20.x - v29.x
v30.x - v39.x
v40.x - v49.x
v50.x
v51.x
v52.x, v53.x
v54.x
v55.x
v56.x
v57.x
v58.x
v59.x
v60.x - v69.x
v70.x
v71.x
v72.x
v73.x
v74.x
v75.x
v76.x
Table 3.19 - Continued
Description
Special screening for endocrine, nutritional, metabolic, and im-
munity disorders
Special screening for disorders of blood and blood-forming or-
gans
Special screening for mental disorders and developmental hand-
icaps
Special screening for neurological, eye, and ear diseases
Special screening for cardiovascular, respiratory, and genitouri-
nary diseases
Special screening for other conditions
Genetics
Body mass index
Estrogen receptor status
A transport accident
Place of occurrence
Accidental poisoning
Misadventures to patients during surgical and medical care, and
abnormal reaction to treatment
Accidental falls
Other accidents
Late effects of accidental injury
Drugs, medicinal and biological substances causing adverse ef-
fects in therapeutic use
Suicide and self - inflicted injury
Homicide and injury purposely inflicted by other persons
Legal intervention
ICD-9 Code
v77.x
v78.x
v79.x
v80.x
v81.x
v82.x
v83.x - v84.x
v85.x
v86.x
e800.x - e848.x
e849.x
e850.x - e858.x,
e860.x - e869 .x
e870.x - e876.x,
e878.x - e879.x
e880.x - e888.x
e890.x - e928.x
e929.x
e930.x - e949.x
e950.x
e960.x
e970.x
e959.x
e969.x
e978.x
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Table 3.19 - Continued
Description ICD-9 Code
Injury undetermined whether accidentally or purposely inflicted e980.x - e989.x
Injury resulting from operations of war, or terrorism e979.x, e990.x -
e999.x
Table 3.19 Grouping of ICD-9 Codes, "x" at the end of a code stands for any number.
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